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ABSTRACT 
Vaccines play an essential role in public health. Adjuvants increase 
immunogenicity for many of these vaccines by stimulating the innate immune 
system: driving cytokine secretion to induce local and systemic pro-inflammatory 
states, upregulating costimulatory molecules on antigen presenting cells (APCs), 
and increasing antigen uptake and presentation to better engage T cell 
responses. Neisseria meningitidis porin PorB is a Toll-Like Receptor 2 (TLR2) 
ligand with broad immune stimulating functions and can act as a vaccine 
adjuvant. Our lab is interested in characterizing how PorB activates the immune 
system and how these effects relate to its adjuvant activity. An understanding of 
adjuvant functions will allow for the rational , rather than empiric, design of future 
vaccines. Here we further investigate the effects of PorB on the innate immune 
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system as it may apply to the adjuvant activity of the porin. In a direct test of 
adjuvanticity we show that without the presence TLR2 the adjuvant activity of 
PorB, measured by antigen-specific lgG production, is diminished in immunized 
mice while loss of MyD88 entirely ablates PorB adjuvant activity. We 
demonstrate costimulatory molecule upregulation in response to PorB stimulation 
and its dependence on TLR2. We show that stimulation with PorB increases 
antigen uptake by APCs and drives APC migration to draining lymph nodes, 
which appears to be dependent on TLR2 and not on MyD88. Finally, we use 
systems vaccinology to uncover complex regulatory networks and dynamics. The 
inclusion of PorB as an adjuvant in a multi-injection vaccine formulation has two 
major effects on expression profiles in murine splenocytes. Vaccine preparations 
containing PorB as an adjuvant induce expression in inflammatory and immune 
signaling networks, in agreement with previous work, and accelerate the kinetics 
of the immune response, as demonstrated by induction of expression of cell 
cycle and proliferative genes and regulatory networks at earlier time points as 
compared to preparations not containing PorB. This systems biology approach 
reveals previously unappreciated aspects of reaction of the immune system to 
PorB. Together, these findings deepen our understanding of the immune 
response to PorB and offer potential insight into the mechanisms behind its 
adjuvanticity. 
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Introduction 
Vaccines have proven to be one of medicine's most effective tools in the 
fight against infectious diseases. From early variolation an~ Jenner's cowpox 
experiments, through the development of attenuated vaccine strains, to modern 
adjuvanted subunit vaccines, infection by dozens of once life-threatening 
pathogens can now be prevented. There remains, however, a pool of infectious 
diseases that have resisted all efforts to design effective vaccines. Malaria, HIV, 
tuberculosis, and a swath of emerging pathogens all present unique challenges 
to vaccine design. The largely empiric methods that have been used in the 
development of our current vaccines have been inadequate to this challenge. As 
immunologists we are left with a need to better understand how the vaccines and 
tools that we do have work, before we can attempt to rationally design new 
vaccines. 
Any vaccine that can provide long-lasting immunity must work with both 
the innate and the adaptive arms of the immune system. These two branches 
must work in concert to recognize and respond to a vaccine, and produce a 
robust immune response. In addition to sensing the presence of invading 
pathogens and acting as a first line of defense, the innate immune system is 
responsible for shaping, to a significant degree, the nature ·of the adaptive 
immune response. It has become apparent that there are qualitatively different 
forms of adaptive immunity that have evolved to respond to the wide variety of 
infectious diseases humans have been exposed to. Determining how strongly 
and down which of those paths the adaptive response will react is determined in 
large part as the innate immune system recognizes and responds to features of 
the pathogen or vaccine. Recent research in innate immunity has made 
significant progress in understanding the pathways that lie between recognition 
of, and reaction to, a pathogen and the final nature of the immune response. 
Cells of the innate immune system recognize pathogens through an array 
of Pattern Recognition Receptors (PRRs). On the surface of innate immune cells 
the Toll-Like Receptors (TLRs), C-Type Lectins (CLEC) and other receptors are 
specific for various Pathogen Associated Molecular Patterns (PAMPs). Internal to 
the cell are additional TLRs, viral nucleic acid sensing helicases, and the NOD-
Like Receptors (NLRs) that can signal through the inflammasome. The 
proliferation of these sensors in the literature has resulted in a nearly 
overwhelming number of possible targets for vaccine and adjuvant design. 
Mimicking the structures of native ligands, designer PAMPs have become the go-
to choice for new vaccine adjuvants. A number of popular options are available to 
the researcher. Monophosphoryl Lipid A (MPL) is a detoxified variant of LPS 
derived from Salmonella, a TLR4 ligand, and is perhaps the leading candidate 
making its way through clinical trials. [1] CpG DNAs are short oligomers of 
nucleic acids with methylation designed to mimic bacterial chromosomes, and a 
TLR9 agonist. The saponin QS-21 and related members are plant-derived 
adjuvants whose mechanism of adjuvanticity is still being elucidated even as they 
have already entered clinical trials in a number of vaccine formulations. Making 
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sense of the wide variety of possible responses may require the use of 
systematic tools for rational vaccine design. Our lab studies the outer membrane 
Porin proteins of Neisseria species, which we have shown to be ligands of TLR2 
[2]. 
An introduction to the study of adjuvants lies in the intersection between 
vaccines and innate immunity. I will begin with how the selection of vaccine 
components can influence aspects of the immune response, including the T 
helper profile [3]. From there, I will discuss the underlying innate targets of the 
vaccine that can effect these changes, focusing on dendritic cells [4], their 
subtypes [5], and the tools available to vaccine designers to select subsets of 
cells (6]. This will also include an analysis of emerging targets, including specific 
vehicles, formulations, and vaccine adjuvants. Finally, I will step back to take a 
more holistic approach, and report on the use of systems biology as a tool for 
vaccinologists in predicting and analyzing innate immune responses. 
Adjuvants and vaccines 
The "dirty little secret" [7] of vaccines has long been trace contamination 
with PAMPs: ligands for a wide range of extra- and intra-cellular Pattern 
Recognition Receptors (PRRs) [8]. The innate immune system has evolved 
multiple classes of PRRs, including the well-known TLRs [9] and NLRs[1 0]. 
Binding of these receptors by PAMPS activates cells of the innate immune 
system, which in turn can promote a stronger response by cells of the adaptive 
immune system [11-13]. Pathogen-derived molecules have therefore come under 
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intense scrutiny as potential adjuvants for vaccines, especially subunit vaccines 
where the antigen itself is not highly immunogenic [14, 15]. Extensive evidence 
exists of immune stimulation through TLR signaling which demonstrated 
increased chemokine and cytokine production, up-regulation of co-stimulatory 
molecules and cell proliferation [16, 17]. Common members of signaling 
networks, especially MyD88 [18-20], have also been observed to play a critical 
function in responses to PAMPs [21, 22]. Currently, adjuvant selection for 
vaccines is determined primarily through extensive and costly empirical clinical 
testing of multiple adjuvant systems [23]. From a rational vaccine design 
standpoint, it should be possible to pick and choose among the vast array of 
available PAMPs for specific vaccine adjuvants each tailored to a desired 
outcome [3, 8]. For this to be possible, however, a more detailed knowledge of 
the molecular mechanisms behind each ligand, and the skewing of the immune 
response generated by the presence of those ligands, is required. To this end, I 
set out to characterize, in more detail, the pathways activated by one particular 
TLR2 ligand, the outer membrane protein (OMP) Porin B (PorB) from Neisseria 
meningitidis [24]. 
Our laboratory has focused on investigating PorB and its interactions with 
the innate immune system. We have identified PorB as an agonist of TLR2ffLR1 
heterodimers [2, 25] and reported its ability to act as an adjuvant when used in 
conjunction with a wide array of antigens [26, 27]. As a member of family of gram 
negative porins, PorB forms a trimeric ~-barrel structure on the outer membrane 
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of the bacteria, and serves as a pore for ion exchange [24, 28]. In addition to 
identifying Por8 as a TLR2/1 agonist, we have also made initial characterizations 
of the innate and adaptive response to the adjuvant in vitro; Por8 increases 
surface expression of MHCII and CD86 on murine DCs and 8 cells and 
stimulates the release of lnterleukin-6 (IL-6) and Tumor Necrosis Factor a (TN F-
a) [29-32]. We have also studied Mitogen Activated Protein Kinase (MAPK) 
activation in response to Por8 in 8 cells, focusing on the Erk1/2 pathway [33, 34]. 
Demonstrating that these effects are TLR2 dependent is, therefore, of interest in 
confirming the molecular mechanisms underlying the adjuvanticity of Por8. 
Manipulating cytokine profiles 
A full review of the adaptive responses observed in Th1 (35, 36] versus 
Th2 [37] or Th17 [38] skewed immune responses, plus the impact of additional T 
helper subtypes such as the T follicular helper (Tfh), [39] is beyond the scope of 
this introduction. In brief, Th1 responses are driven by one family of cytokines 
including IFN-y and IL-12, while Th2 profiles are observed in response to 
alternative factors, classically IL-4. Other cytokines, such as IL-1 0, can suppress 
the immune response by generating T regulatory (Treg) cells. [40] Early 
investigation into the roles pathogens play in this process observed Th1 
responses to viral infections, while bacteria and helminths elicited more balanced 
or Th2 profiles. Further work has uncovered the transcription factors T -bet and 
GATA-3 as central to the differentiation ofTh1 and Th2 CD4+ T cells 
respectively. With the discovery of the PRRs, efforts were made to classify the 
5 
nature of the T helper response to ligands of each receptor. While some trends 
have emerged, enough conflicting results have been reported that the field 
requires extensive review to encompass the full body of work [12]. However, 
recent work in the development of vaccines designed to generate cytokines that 
tend to drive such responses in one direction or another, and the innate immune 
mechanisms behind the secretion of these cytokines, can be addressed here. 
As desirable as robust cytokine responses are in animal models as 
demonstrators of efficacy and immunogenicity, they must be carefully managed 
as novel products move towards the clinic. Very high cytokine responses, and 
their associated adverse effects, including pain, inflammation and injection site 
reactions , are the reason highly potent experimental adjuvants like Complete 
Freund's Adjuvant (CFA) and unmodified LPS are non-viable as clinical 
adjuvants. Overly aggressive stimulation of the innate immune system by 
adjuvants has also been linked to the development of autoimmunity; adjuvants 
have been used intentionally for this purpose in animal models [41, 42]. 
Conversely, sensitivity to innate cytokine responses may be a distinguishing 
feature of some live attenuated vaccine strains, as demonstrated by work on a 
Japanese encephalitis virus vaccine candidate [43] in which the increased 
immunogenicity of the attenuated strain was linked to its ability to elicit more 
robust cytokine responses than the pathogenic strain. 
Most modern vaccine design efforts , and almost all of those towards viral 
pathogens, have been focused on generating primarily Th1 responses. [39, 44] 
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This is done with the goal of developing a robust cellular immunity [45] in addition 
to long-lasting humoral immunity while the avoiding allergic or tollerogenic [46] 
and auto-immune type responses [47] that are more closely affiliated with the 
Th2 and Th17 phenotypes respectively. Although almost all current vaccines 
offer protection through humoral immunity [48], design strategies for pathogens 
that have resisted efforts to date are focused on cellular immunity, based on the 
hypothesis that this may be protective in cases where humoral immunity has 
proven difficult to elicit or non-protective. 
Skewing of the adaptive immune response by a vaccine to a desired T-
helper profile begins with the innate immune system. The two most readily 
avai lable tools for this purpose are the selection of adjuvant(s) and delivery 
vehicle, which together with the antigen of choice make up a subunit vaccine 
formulation. Once in vivo, differentiation of antigen specific CD4+ T cells into a 
Th1 or Th2 response is driven by local cytokine production and the expression of 
cell surface molecules by members of the innate immune system, especially in 
the context of peptide presentation on MHC [3] . While attenuated, inactivated or 
Virus Like Particle (VLP)-Iike vaccines (including DNA vaccines) may blur the 
lines between antigen, adjuvant, and vehicle, in the case of subunit vaccines 
these effects on the innate immune system can be ascribed to the adjuvant 
and/or vehicle even in the absence of antigen [49, 50]. Within the GSK Adjuvant 
Series (AS01-AS04), the combination of alum and MPL known as AS04 and 
used in the HPV vaccine elicits TN F-a and IL-6 plus additional chemokines [51]. 
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The combinations of MPL and the saponin QS-21 in liposomes (AS01) or an oil 
emulsion (AS02) have been compared in head-to-head tests for their ability to 
elicit responses from various CD4+ T cell subsets [52-54]. AS02-adjuvanted 
vaccines have been observed to drive production of IL-2, TNF-a and IFN-y, all 
associated with Th 1 responses [55]. This work was done using antigens from 
Mycobacterium tuberculosis, and despite the secretion of Th1 cytokines, no 
antigen-specific CDS+ cytotoxic T cells were detected. In some studies AS01 has 
been observed to generate higher numbers of IL-2 and IFN-y producing CD4+ T 
cells when compared to AS02 [52]. Both AS01 and AS02 were observed to 
generate larger cytokine responses than the antigen, a VZV glycoprotein, paired 
with alum or given without adjuvant in saline. Similarly, a report on the innate 
effects of the AS04 adjuvant formulation (MPL + alum) showed increased 
production of the cytokines TN F-a and IL-6, but not IFN-a, when compared to 
alum alone [51]. Reports of this nature on AS04 are particularly relevant given its 
recent approval for use in prophylactic vaccines for HPV. Moreover, these effects 
were observed to be specific to the innate immune system, affecting dendritic 
cells, but not T cells. Working on the TLR2 agonist Porin B (PorB) from Neisseria 
meningitidis [2], our lab has shown it to elicit a combination of Th1 and Th2 
associated cytokines [29]. 
These papers do highlight one somewhat common deficiency in most 
reports on modern adjuvants: because of the relatively recent proliferation of new 
adjuvants, most comparisons in the literature are made to alum, with saline as a 
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negative control. This does have the advantage of providing a widely comparable 
reference point, and in highlighting the improvements of novel adjuvants over the 
standard of care. Novel vaccines, however, are not choosing between alum and 
a single novel adjuvant, but from the whole spectrum of new options. Alum may 
even inhibit key Th1 cytokine responses like IL-12 [56] , leading to artificially high 
differential responses when it is used as a control for other adjuvants. Head-to-
head comparisons between novel adjuvants, while rarer, thus provide more 
relevant information in researchers interested in candidate vaccine formulations. 
The increased effectiveness of AS01 was also observed in human subjects 
vaccinated with three different GSK Adjuvant Systems, where the liposomal 
formulation outperformed two different oil-water emulsions using HIV derived 
antigens as determined by antibody titers and CD4+ T cell responses [53]. 
However, as reasonable as these observations are in assessing the performance 
of each system from a theoretical perspective, the usefulness of these 
observations as clinical correlates of protection has not been established. The 
occasionally contradictory nature of head-to-head results, especially when using 
different antigens and model systems, has made generalizable predictions 
difficult, if not impossible. As discussed later in this introduction, it may be that 
systems vaccinology offers the best hope for tools to handle this complex 
problem. 
Dendritic Cells 
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Dendritic cells (DCs) play an essential role in communication between the 
innate and adaptive arms of the immune system. In the peripheral tissues, DCs 
sample the environment. Upon antigen capture and the presence of a danger 
signal, DCs undergo maturation and migration to the secondary lymphoid 
tissues, where they present antigenic peptides on MHC toT cell populations, 
directing the development of the cellular immune response. Presentation of 
antigen to T cells, expression of costimulatory factors , and secretion of various 
cytokines and chemokines are all essential functions in strengthening the 
adaptive immune response [57]. In this section, I will cover various new 
approaches both to targeting vaccines to dendritic cells and eliciting desired 
responses from those DCs. 
A wide range of professional APCs reside in the body, each with a 
specificity and affinity for certain innate immunity pathways. Of particular interest 
are the various subtypes of dendritic cells. These have been observed to carry 
out particular functions, including migratory and resident populations, or with 
affinities for CD4+ vs. CDS+ T cells. Expression of PRRs, expression of 
costimulatory factors including CD40, COSO and CDS6, and secretion of 
cytokines, have all been observed to vary between DC subtypes. Upregulation of 
some or all of these factors by migratory or lymph node resident DCs has been 
taken to be a measure of activation of the innate immune system by vaccine 
formulations [51] . Clarification of the roles of each subtype and identification of 
markers that can be used to target these types is therefore a highly useful field of 
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work. Given the known differences between the behavior of e.g. plasmacytoid 
DCs (pDCs) in mice and humans, identifying comparable subtypes between the 
two species is also necessary to translate experimental formulations in clinically 
relevant candidates. Towards this end , the identification ofa migratory DC 
population in humans capable of cross-presentation , identified by high CD141 
expression and similar to the well-studied CD1 03+ population in mice, is of 
particular note [4]. 
"Dendritic cell vaccines" per se have also gathered a great deal of 
attention. These vaccines are composed of ex vivo antigen-pulsed and expanded 
autologous dendritic cells transferred back to the donor, with the intent to present 
those antigens to the adaptive immune system in a highly selective manner. The 
primary use of this technology to date has been in the development of cancer 
immunotherapies. [58] While the research presented here does not involve 
dendritic cell vaccines per se, many of the same response elicited in vitro when 
DCs are activ-ated are also desirable as in vivo responses to vaccine injections 
[59-61]. 
Active targeting of antigens to dendritic cells is a rapidly advancing field. 
Antigen-lgG constructs have been used for over 25 years to deliver proteins of 
choice to dendritic cells by fusing antigens to antibodies specific for dendritic cell 
surface molecules [62]. More recently, targeting to specific DC subsets has been 
achieved with the use of antibodies or ligands specific for surface molecules with 
restricted expression [6, 63, 64]. As dendritic cell subsets have been observed to 
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process antigens in varied manners, targeting antigens toward particular subsets 
can be used to shape the immune response to a desired end [5]. While a large 
proportion of research is currently directed towards enhancing Th1 and cellular 
responses, efforts solely towards robust antibody responses have also been 
investigated. 
Among the ligands used for targeting, those recognized by PRRs, and in 
particular the TLRs, have been of especial interest. Direct conjugation or indirect 
attachment of an antigen or vehicle to a TLR ligand offers the attractive 
combination of targeting to, and activation of, an APC upon binding. Direct 
conjugation of TLR ligands to antigens has been widely used as a means of 
enhancing immune responses to a greater extent that observed when mixing the 
antigen and adjuvant before injection. Conjugation of the TLR9 ligand CpG to 
Ova was observed to escape the requirement for a helper T cell population in 
generating a robust CTL response [65]. Experimentation with other TLR ligands 
as conjugated adjuvants has included the TLR7 agonist imidazoquinolines, 
observed to promote cross-presentation [66], and the TLR5 agonist flagellin [67]. 
Influenza HA fusion proteins based on flagellin have proceeded to Phase I 
clinical trials, where they showed reasonable safety profiles and imunogenicity 
[68]. Conjugation of the antigen with adjuvant additionally allows for a substantial 
reduction in the antigen dose required to elicit a robust response, a not 
insignificant factor in translational work focused on developing clinically viable 
vaccine formulations. 
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The C-type lectins are a family of carbohydrate-binding proteins with roles 
from cell-cell adhesion and motility to pathogen recognition and immune 
response. Lectins have emerged as a rich set of candidates for targeted delivery 
of antigens to specific DC subsets. The CDS+ DEC205+ family of DCs reside in 
the T cell zone of secondary lymphoid tissue and specialize in the presentation of 
antigen to CTLs [5]. DEC205 has recently been used for targeting an HIV 
vaccine designed to induce cellular immunity [69], and a DNA vaccine to two self 
antigens [70]. The lectins CLEC9A [71] and macrophage galactose-type C-type 
lectin (MGL) [72] have also been targeted and their responses characterized. 
Recently, effort has been made to conduct head-to-head comparisons to some of 
these lectins [69]. Comparable responses were observed when using fusion 
constructs of the HIV p24 protein and mAbs to Langerin, DEC205, and CLEC9A. 
As the lectins have their own natural ligands, investigation has also been made 
into the relative efficacy of using monoclonal antibodies or native ligands for 
targeting. Using DC-SIGN as the DC-expressed target, mAbs were found to be 
the most effective in driving the presentation of antigenic peptides on Class I 
MHC, and equivalent to the HIV ligand gp120 while superior to carbohydrates for 
presentation on Class II MHC [73]. 
If the science of cytokines and T helper cells is moving into the bedside, 
the study of dendritic cell responses to vaccines remains within the basic 
sciences. New dendritic cell populations are still being discovered and their role 
in the innate immune response fleshed out. Reagents are still being developed 
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that can target vaccines to specific DC subsets, either to surface molecules that 
define certain subsets or based on the pattern of expression of PRRs. The next 
step will be to understand the influence of incorporating such reagents on the 
nature of the immune response to vaccines. Comparisons will need to be made 
between antigen-lgG fusion constructs that target extremely specific cell 
populations but may not have pro-inflammatory properties, mixed constructs like 
those targeting the C-type lectins that can be both specific and agonistic, and 
less specific adjuvants like TLR agonist fusion proteins with broad specificities for 
innate immune cells but robust inflammatory properties. 
Antigen presentation and APC migration 
Generating the proper cytokine milieu and targeting an antigen to the 
correct class of DC are necessary steps in the functioning of a vaccine, but they 
are not sufficient for robust interaction between the innate and adaptive immune 
systems. For antigen presentation to occur, at least two more conditions must be 
met. First the antigen must be taken up by the APC, processed by proteolytic 
machinery, and presented in the context of MHC plus necessary costimulatory 
factors. Second, the APC itself must be in a location, generally the secondary 
lymphoid tissue, where it can interact with a sufficient number of na·lve T cells to 
insure it is able to find a cognate member of the adaptive immune system 
capable of recognizing the presented antigenic peptides. An analysis of these 
factors is essential in determining the theoretical efficacy of new vaccine 
formulations. Each of these factors will be discussed in turn below. 
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In order to stimulate a CTL response, APCs must present antigenic 
peptides in the context of Class I MHC. Dendritic cells are able to use multiple 
pathways for this purpose. One of the key factors to eliciting cellular to a vaccine 
is access to one or more of these pathways. During infection with live attenuated 
viruses, or transfection with DNA or RNA vaccines, expression by APCs of 
foreign proteins allows direct loading of peptide onto MHC through the 
endogenous processing pathway. In subunit and inactivated vaccines, APCs are 
able to capture, process, and present antigen on Class I MHC through a process 
known as cross-presentation [74].The importance of various elements of the 
vaccine formulation in antigen processing and presentation has been well 
recognized. The original work in the field demonstrated not only the importance 
of PAMPs, in this case TLR ligands, but also the physical association of the 
PAMPs with the antigen, as regulation of the antigen processing machinery is 
done at the scale of individual endosomes [75, 76]. Recent analyses of vaccine 
formulations first focus on the internalization of soluble antigens in vitro or in vivo 
as measured by the acquisition of fluorescently labeled antigens [51]. 
Demonstrating this effect for subunit vaccines has involved work with antigen-
adjuvant fusion constructs as discussed above, to some success. 
Migration of antigen-loaded APCs to draining lymph nodes where they are 
able to efficiently stimulate cognate T lymphocytes is an essential process in the 
functioning of the innate immune system. New basic science tools are being 
developed to study these interactions, even as the efficacy of individual 
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adjuvants and vaccine formulations are being studied. The primary technique is 
to use fluorescently labeled antigens and to characterize the changes in the 
antigen-positive cell population in draining lymph nodes after vaccination. AS04, 
for instance, was shown to increase the number of antigen-positive DCs when 
compared to vaccination with alum alone, as well as the expression of some co-
stimulatory molecules (CD40, but not CD86) [51]. Easily performed by flow 
cytometry, this technique also allows for characterization of multiple of features of 
the antigen positive cells, including expression of surface costimulatory 
molecules. However, it is unable to say anything about the association of APCs 
with lymphocytes, and is also restricted in representing a single, static point in 
time. The use of two-photon microscopy has allowed researchers to observe 
single-cell interactions between APCs and lymphocytes in vivo and in real time 
[77]. As the use of this technology has progressed, it has expanded from very 
theoretical investigation of the biomechanics and physiology of the innate 
response [78] into a tool to study the processes of responses of the innate 
immune system to pathogens [79] and subunit antigens [80]. In one study, the 
addition of a TLR4 agonist (LPS) to OVA-coated latex beads was observed to 
both increase migration of antigen-bearing cells to draining lymph nodes and 
extend interactions between those DCs and Ova-specific 0011.10 T cells [81]. 
The ability of two-photon systems to study intact in vivo and ex vivo explants 
under conditions that maintain the organ structure of the lymph nodes is essential 
for these studies. If two-photon systems excel in teasing out specific cellular and 
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molecular interaction, in vitro imaging using IVIS systems [82] offers a systemic 
approach to analyzing the innate response to vaccines [83]. Working with a 
luciferase expressing viral vector, researchers were able to demonstrate that a 
TLR3 agonist was able to prevent the CNS spread of Venezuelan equine 
encephalitis virus. 
Role of IL-1 J3 and MyD88 
The role of the cytokine lnterleukin 1 beta (IL-1 ~)and the inflammasome 
in innate immune responses to vaccines has been extensively studied. Whether 
alum activates the inflammasome in vivo, and whether this plays an essential 
role in its adjuvant activity, has been hotly debated [84, 85]. Interest in the 
inflammasome is by no means restricted to alum, however, and new adjuvant 
candidates are regularly screened for IL-1~ release dependent on one or more 
inflammasome intermediaries [86]. As the downstream mediator of the IL-1 
receptor, as well as an integral component in the signaling cascades of a number 
of PRRs and other signaling pathways, MyD88 plays a crucial role in the 
functioning of the innate immune system. This has been demonstrated for 
pathogens like malaria [22], adenovirus [87], and influenza [18], and for vaccine 
adjuvants [21, 88, 89] including our work demonstrating the role of MyD88 in 
responses to PorB [25]. As such, the effects of various vaccine formulations on 
MyD88-dependent processes have been studied intensely by our lab and others 
[9, 90]. 
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As discussed above, there is a great deal of interest in designing or 
selecting vaccine formulations, specifically adjuvants and vehicles, which drive 
Th1 responses from the innate and adaptive immune systems. Recent work 
looking at the induction of a number of the key cytokines in this process has 
underscored the importance of MyD88 in driving both the induction of cytokines 
including IL-1 ~and Type I interferons, and the cellular response to them [88]. 
MyD88 has also been shown to be essential to the CD8+ CTL response to 
adenovirus-vector vaccines [87]. The authors conclude that this due to TLR 
ligands stimulating the release of IL-12. Work is currently ongoing to map out 
pathways beyond the dogma of MAPK and NF-KB activation by which MyD88 
signaling can regulate innate immune activation and the generation of 
inflammatory responses [21]. 
Non-TLR ligand adjuvants are also capable of activating innate immunity 
through MyD88. The ISCOMATRIX adjuvant [91] has been shown to activate 
APCs and enhance cross-presentation of subunit vaccine antigens to CD8+ T 
cells in a MyD88 dependent manner [20]. The oil-in-water emulsion MF59 has 
also been shown to require MyD88 for its adjuvant effect, despite neither 
signaling through a TLR nor requiring the NLRP3 inflammasome that might 
generate IL-1~ [89]. MyD88 has thus been shown to be essential for both 
humoral responses to vaccines in the generation of and signaling by cytokines 
and in cell-intrinsic processes such as antigen presentation. Additionally, as our 
lab and others have shown, many adjuvants are capable of directly stimulating 
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cells of the adaptive immune system, and MyD88-mediated pathways often play 
a role in such processes, as seen in the stimulation of B cells by VLPs [18] or 
PorB [25]. Conditional MyD88 knockouts in the relevant cell lines may be 
required to tease apart the compound roles played by this widely prevalent 
protein. It should be noted there are situations in which intact My088 signaling 
pathway is not essential for responses to vaccines. In particular TLR3 and TLR4 
can both signal through the alternate TRIF!TRAF pathway. The MenC vaccine, 
for instance, has been reported to be effective in MyD88 KO mice [92]. In this 
case, alternative TLR4 signaling is likely responsible for activating the innate 
immune system. 
Other formulation considerations 
Designing a modern vaccine often requires the selection of one or more 
adjuvants. Historically the choice was simply whether to use alum or not; no 
other adjuvants were clinically licensed. More recently, the available choices 
have broadened to include additional vehicles, including oil emulsions such as 
Novartis's MF-59, and TLR agonists such as the MPL in GlaxoSmithKiine's 
(GSK) AS04 combination formulation of MPL +alum [51]. Experimentally, of 
course, a far wider array of adjuvants and vehicles are available, with specificities 
for almost any PRR desired. Selection of a single candidate for regulatory 
approval, however, remains a largely empirical process, as seen in the efforts to 
select a single formulation for an effective malaria vaccine [23]. Current efforts to 
characterize the innate immune responses to adjuvants specific for each of the 
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various PRRs, and the nature of the adaptive response they generate, may 
however allow for more rational vaccine design in the near future. Difficulties 
arise, however, in the heterogeneous responses observed to single adjuvants, as 
seen in recent reports of Th17 responses to the TLR4 and TLR2 ligands [47, 93], 
usually used as examples of inducers of Th1 and Th2 responses. [3] Choices of 
model, either between strains of mice, or when transitioning from murine to non-
human primate and/or human models, in addition to variability in route of 
vaccination [44] , associated vehicles, and antigen, all complicate direct 
comparisons. PRRs specific to various adjuvants also see expression outside of 
the innate immune system, which can further complicate comparisons. Work in 
our lab has shown route-dependent effects of the TLR2 ligand PorB, as seen in 
its interaction with airway epithelial cells [94] when given as an intranasal vaccine 
to F. when given as an intranasal vaccine to F. tularensis [26]. Similarly, we have 
also observed it to have a direct effect on the adaptive immune system, where it 
triggers the tyrosine kinase and Erk pathways, leading to NF-KB activation in 
murine B cells [33]. Teasing out the innate-specific effects of vaccine 
components from their interactions with outside systems remains an ongoing 
challenge in the field. 
Vehicle design to trigger innate immunity 
In the past two decades, the design and selection of adjuvants has been 
at the forefront of subunit vaccine design. Given their ability to trigger Pattern 
Recognition Receptors, and the known effects PRRs have on the innate immune 
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system, this is of no surprise. Recently, however, an increasing focus has been 
placed on other aspects of the vaccine formulation. Specifically, the nature of the 
vehicle carrying the antigen and adjuvant has been the topic of a great deal of 
study, both in the development of new vehicles, and elucidating the contributions 
of said vehicles to the nature of the innate and adaptive immune response. In 
addition to the classical adsorption of antigen onto alum [14, 95-97], oil-water 
emulsions [44, 54, 96, 98, 99], liposomes [52, 100, 101 ], and more complex 
nanoparticles [49, 1 02] have all been studied . 
There are numerous roles believed to be played by the vehicle in a 
vaccine formulation. The initial hypothesis for the effectiveness of alum, and one 
still discussed for new vehicles, is a depot effect whereby the association of the 
antigen with the vehicle keeps it held at the injection site, preventing washing out 
of the antigen and allowing more time for phagocytosis by APCs or interactions 
with the BCR of surveying B cells. Certain vehicles are theorized to affect antigen 
uptake and processing by APCs. This effect has been well studied in regards to 
TLR ligands and adjuvants [75, 76], and may play a role in some vehicles as 
well. Finally, certain vehicles may be associated with greater releases of 
cytokines or increased expression of costimulatory molecules on the surface of 
innate immune cells. 
Systems biology and assaying innate cells 
A discussed here, systems biology offers a suite of tools for analyzing the 
complex regulatory and signaling networks involved in the immune response to 
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vaccines. With knowledge of these networks, one can make queries of a model 
based on various assumptions about a vaccine candidate. The output of such a 
model can then be used as-is, as a hypothesis for the nature of the immune 
response that vaccine would provide. More thoroughly, if the nature of a 
protective response to the pathogen in question is known, it is possible to 
compare multiple vaccine candidates to determine which one would be 
hypothesized to have a response most closely mimicking that of known 
resistance to infection. From a more basic research approach, systems biology 
can allow researchers to examine the regulatory network itself, to understand 
which components are most essential in establishing robust immune responses 
[1 03]. From there it may be possible to proceed with more rational vaccine 
design targeted towards such essential or high-yield pathways. 
One heavily used aspect of systems biology has been to mine the 
genomes of pathogens to find strong candidate antigens [104]. From such 
highlighted antigens vaccine design can then progress using a restricted set of 
proteins or peptides, greatly accelerating the process of vaccine development in 
a process often termed "reverse vaccinology" [1 05]. Common approaches 
include looking for evolutionarily conserved genes that will resist antigenic drift 
and selection, and identifying peptides or proteins with epitopes likely to be 
presented on Class I & II MHC, or that may generate protective antibody 
responses [1 06]. While I did not investigate antigen selection, the tools 
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developed for it [1 03] have applications in our work on those aspects of systems 
biology that relate to innate immunity, its pathways, and its functions. 
There is an extraordinary wealth of information available relating the 
myriad interconnections between elements of the innate immune system. 
Signaling pathways, cell-cell communications, and regulatory networks have all 
been reported on for thousands of genes, proteins, and cells. Simultaneously, 
expression profiling using microarrays and deep sequencing can give us 
transcriptomes of tissues and cells of interest following stimulation with any 
vaccine formulation desired [96]. The challenger for the researcher, then, is 
finding and using the correct tools of the former to analyze the data of the latter. 
Given the large number of possible outcomes measurable for any adjuvant or 
formulation, head-to-head comparisons have been difficultin the past short of 
empirical clinical trials. Such trials, while the gold standard in selecting a final 
formulation with which to seek regulatory approval [23], are prohibitively 
expensive for all but the most promising vaccine candidates, and may slow the 
introduction of more experimental adjuvants. In contrast, systems biology 
approaches provide very broad analyses of vaccine formulations, allowing 
comparisons across as many outcomes as the researcher wishes to choose. A 
recent comparison of alum against MPL, for instance, was able to confirm narrow 
cytokine results with broad transcriptome evidence supporting an increased 
innate immune response to the TLR 4 ligand [3]. Similarly, a comparison of MF-
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59, alum and CpG DNA used as adjuvants and sampling the injection site 
identified a core of 168 genes regulated by all three [96] . 
Systems biology approaches can also be used to study the efficacy of 
individual vaccines in various patient populations. A study of vaccine responses 
in children, including a comparison to atopic responses to allergens, 
demonstrated the importance of the Th1 /IFN networks. In the immunogenic 
response to the diphtheria/acellular pertussis/tetanus and pneumococcal 
polysaccharide conjugate vaccines this network was balanced in the Th2 
response, whereas it was blocked in the allergenic response [1 07]. Given the 
heterogeneity of the human patient population in contrast to inbred mouse 
models, describing responses across a range of backgrounds will be important in 
predicting the efficacy of vaccines that -might be given to children, the elderly, or 
patients with compromised immune systems. Descriptive research like this works 
well to describe important regulatory networks and the key players among them. 
To be of greater use in the design of new vaccines and allow for greater in silica 
development, however, predictive models need to be accurately forecast the 
response to changes in vaccine formulation. 
Neisseria meningitidis porin PorB 
Molecules purified from pathogens and their derivatives can have many of 
the properties desired in adjuvants, driving cytokine release [1 08], adjuvant 
uptake [75], and APC activation [1 09]. This has led to the advancement of many 
such PAMPs as adjuvant candidates. Research in our lab, and work performed 
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for this dissertation, focuses on a protein purified from Neisseria meningitidis, a 
Neisseria! major outer membrane protein, which is a porin and is termed Porin 8 
(Por8). Por8 is an outer member membrane protein and comprises 50-60% of 
the outer membrane protein content on the meningococcus [26, 27]. As a 
member of family of gram-negative porins, Por8 forms a trimeric 13-barrel 
structure on the outer membrane of the bacteria, and serves as a pore for ion 
exchange [24, 28]. When isolated and purified , Por8 in suspension forms nano-
scale structures known as proteosomes [24, 11 0] . Proteosomes are all-protein 
micelles, formed in the absence of any lipids, the presence of which would make 
the structure a liposome. The immunologic activity of the porins was first 
identified when using outer membrane vesicle preparations as vaccine 
candidates; it was recognized that Por8 was capable of stimulating the immune 
system in the absence of other adjuvants [111, 112]. We have identified Por8 as 
an agonist of TLR2!TLR 1 heterodimers [2, 25] and reported its ability to act as an 
adjuvant when used in conjunction with a wide array of antigens., including 
proteins [111 ], polysaccharides [30], and liposaccharides [26]. In addition to 
identifying Por8 as a TLR2/1 agonist, we have also made initial characterizations 
of the innate and adaptive response to the adjuvant in vitro; Por8 increases 
surface expression of MHCII and CD86 on murine DCs and 8 cells and 
stimulates the release of lnterleukin-6 (IL-6) and Tumor Necrosis Factor a (TNF-
a) [29-32]. We have also studied Mitogen Activated Protein Kinase (MAPK) 
activation in response to Por8 in 8 cells, focusing on the Erk1/2 pathway [33, 34]. 
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Despite the advances our lab and others have made in understanding the 
response of the immune system to PorB, many areas of its activity remain 
unexplored. The purpose of this thesis will be to address these other aspects of 
PorB immune stimulation and to answer questions that remain outstanding. Of 
note, while CD86 upregulation had been shown to be essential for PorB adjuvant 
activity and CD86 upregulation in response to PorB has been shown to be 
dependent on TLR2 and MyD88, as discussed above, the overall dependence of 
the adjuvant activity on TLR2 and MyD88 had not been conclusively 
demonstrated. This work also examines the effect of PorB on macrophage 
activation and activation marker expression, as has been examined for dendritic 
cells [90). Characterization of the innate immune stimulating effects of PorB, to 
date, has focused on upregulation of cell surface proteins and secreted 
cytokines. While antigen uptake, processing and migration-of APCs are known to 
be important for innate immune communication with adaptive immunity, the effect 
of PorB on these pathways had not yet been investigated, therefore, the effects 
of PorB on these pathways shall also been examined in this dissertation .. 
As discussed above, systems vaccinology has recently greatly expanded 
the range of tools available to study the response of the immune system to 
vaccine formulations. A survey of the transcriptome response to PorB was 
performed to enable an initial survey of the regulatory networks affected by PorB 
to potentially reveal previously unknown pathways and signals that could be 
related to PorB's adjuvant activity. Development of this resource would also allow 
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for future comparisons of PorB to other adjuvants. Analysis across the breadth of 
the multi-injection schedule was a new approach that had not previously been 
undertaken for any adjuvanted vaccine, and by doing so, would allow us to 
uncover previously unappreciated modes of regulation that would remain unseen 
if the responses to PorB at only a single time-point were investigated. Together, 
these goals allowed an approach that remained hypothesis-driven while still 
allowing for the discovery of unexpected results. 
Conclusions 
The adjuvant and vaccine development field has been making rapid 
progress in recent years thanks to a greater understanding of the roles played by 
innate immunity and their importance in the robust functioning of vaccines. There 
are multiple pathways through which innate immunity can influence the efficacy 
of a vaccine, and rational vaccine design must incorporate as much of this 
knowledge as possible. Once, it was sufficient simply to include an adjuvant or 
vehicle that would activate at least one PRR or otherwise activate the innate 
immune response. Now new research has shown that the selection of vaccine 
components plays an important role in cytokine profiles, targeting the vaccine to 
specific APCs, influencing antigen uptake, processing and presentation, and 
potentially other factors too numerous to classify by traditional molecular biology. 
With the sometimes bewildering array of options now available to vaccinologists, 
choosing the formulation that will interface with the innate immune system in 
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such a way as to elicit the desired protective response has become much more 
daunting. 
Manipulating cytokine profiles in vaccine responses is a means to an end. 
With the identification of the transcription factors that regulate T helper subtypes, 
it has become possible to predict, with some confidence, the skewing of the 
response to some vaccine adjuvants. While "standardized" cytokine profiles have 
been developed for the most commonly used experimental adjuvants, 
comparisons between adjuvants are still difficult due to the relative scarcity of 
such reports in the literature, often conducted under a wide variety of 
experimental conditions. Multi-component formulations and adjuvants that elicit 
mixed responses also present difficulties. More challenging still is that while 
theoretical models may predict that one type of a response or other will be more 
effective in vaccines, robust correlates of protection do not exist for many of the 
pathogens with vaccines in development. From the perspective of the 
vaccinologist, then, the field appears to be at a tipping point. A great deal of basic 
science knowledge has been accumulated; the challenge is now to successfully 
apply it to translational and clinical applications in a rational, rather than 
empirical, manner. 
As the above discussion has pointed out, there are an ever-increasing 
number of factors that must be considered in the design of a modern vaccine. 
Accurately assessing the impact of individual elements of a vaccine formulation, 
much less their interactions, may already be moving past the abilities of 
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traditional molecular biology. Systems vaccinology offers the promise of tools to 
handle the multitude of pathways involved in the response to complex vaccines 
and their implications for a heterogeneous patient population. The current state 
of the field has shown promise in identifying key regulatory pathways in vaccine 
responses and proposing hypotheses for the differences observed in responses 
within or between patient groups. Progress remains to be made, however, in 
efforts to predict the efficacy of novel vaccines or changes to current vaccine 
formulations. 
The eventual goal of vaccine research is the development of protective 
vaccines for epidemiologically relevant diseases. Many of the most intensely 
studied targets are widespread pathogens that have resisted previous efforts to 
create fully protective vaccines, including Tb, HIV and malaria. Indeed, some 
positive progress is being made on these fronts. However, there exist a far 
greater number of emerging infectious diseases waiting in the wings, not to 
mention efforts underway to develop therapeutic vaccines to cancers. If any 
progress is to be made against these highly variable diseases in a rational 
manner, it will be by applying the lessons learned in the design of current 
vaccines. Although the antigens we use may bear no resemblance to each other, 
the elements of the innate immune system that interact with our vaccines will 
stay the same. By better learning how to harness the incredible power of innate 
immunity to recognize, alert and inform, we will be ready to meet these 
challenges. 
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Methods 
Mice 
Six week old female C57BU6 mice were obtained from Jackson 
Laboratories (Bar Harbor, ME). MyD88 KO [113] and TLR2 KO mice [114] (on 
the C57BU6 genetic background) were a gift from Dr. S. Akiria (Research 
Institute for Microbial Diseases, Osaka University, Osaka, Japan). All mice were 
maintained within the Laboratory Animal Science Center (LASC) at Boston 
University School of Medicine under specific pathogen free (SPF) conditions. The 
Boston University Institutional Animal Care and Use Committee approved all 
research on animal models. 
Subcutaneous vaccinations and serum collection 
C57BL/6, TLR2 KO and MyD88 KO mice were vaccinated subcutaneously 
as described previously [29]. Vaccines were delivered via 28G needle (BD 
Biosciences) underneath the skin at the nape of the neck, behind the ear. 
Vaccine formulations used 10 IJg of lyophilized chicken egg Ovalbumin (Ova) 
with or without 10 IJg PorB in 100 IJL PBS per mouse. Control mice were given 
sham vaccines containing only 100 IJI PBS. 3 doses were given on days 0, 14 
and 28; blood was obtained from the tail vein on days -1 , 13, and 27. On day 42, 
mice were humanely euthanized with C02 and terminal bleeds were obtained via 
cardiac puncture. Sera were purified by centrifugation and were frozen at -80 oc 
until use. 
30 
PorB and Ova Purification 
PorB was purified from N. meningitidis strain H44/76 ~-1/4 that lacks PorA 
and RMP (reduction-modifiable protein) [115] as described previously [24]. 
Bacteria were plated on gonococcal agar plates containing 1% lsovitalex (Becton 
Dickinson) and grown overnight at 3TC with 5% C02 . Colonies were inoculated 
in 50ml50ml of liquid GC medium [110] containing 1.5% proteose peptone 
(Becton Dickinson), 1% lsovitalex, 0.5% sodium chloride, 0.4% potassium 
phosphate dibasic and 0.1% potassium phosphate monobasic (all Sigma 
Aldrich). Liquid cultures were incubated at 3TC with shaking for seven hours, 
then split 1:4 into 4 new cultures (50 ml final volume) in new liquid GC medium 
and incubated for another 7 hours at 3TC with shaking. Each 50 ml culture was 
then added to 1.5 ml of liquid GC media and incubated with shaking at 3TC 
overnight. Bacterial pellets were obtained by ultracentrifugation (Sorvall RC-5C 
Plus Centrifuge, Sorvall Products, Newton, CT, USA) at 5000 rpm for 20 minutes. 
Crude protein extracts were obtained by resuspension of the pellet in 1 M 
sodium acetate containing dimercaptopropanol (Sigma Aldrich) as an anti-
protease. 5% Zwittergent 3-14 (Calbiochem, San Diego, CA, USA) and 0.5 M 
calcium chloride were added to the slurry in a water bath sonicator (Branson 
3200 Ultrasonic Cleaner, Branson Ultrasonics Company, Danbury, CT, USA). 
Ethanol was added to a final 20% v/v concentration to precipitate DNA, LOS, and 
other debris. The suspension was separated by ultracentrifugation as above, and 
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the total protein precipitated by adding 1 00% ethanol to the supernatant to a final 
concentration of 80% v/v and overnight incubation at 4°C. 
The pellet was resuspended in buffer containing 50 mM Tris, 1 0 mM 
EDTA, 5% Zwittergent and 0.02% sodium azide, adjusted to pH 8.0 (loading 
buffer). ion-exchange purification was performed using DEAE-Sepharose and 
CM-Sepharose (Amersham, GE Healthcare, Buckinghamshire, UK) columns (2.5 
x 10 em, Econo column; Bio-Rad, Hercules, CA, USA) at a flow rate of 1.8 
ml/min. [24]. Flow-through was collected until the 280 nm absorbance returned to 
baseline, and the protein precipitated as above in 80% v/v ethanol and 
resuspended in buffer containing 100 mM Tris, 10 mM EDTA, 0.2 M sodium 
chloride, 0.05% Zwittergent, and 0.02% sodium azide, brought to pH 8.0 
(washing buffer). Next, gel filtration chromatography was performed with a 
Sephacryl S-300 (Amersham) column (2.6 x 180 em) at a flow rate of 0.25 
ml/min. The porin containing fractions were identified by Coomassie staining of 
SDS-PAGE gels. Porin containing fractions were pooled and precipitated as 
above, and resuspended in loading buffer, but at pH 7 .6. Removal of endotoxin 
and lipoproteins was performed using a Matrex Cellufine Sulfate (Millipore, 
Billerica, MA, USA) column (2.5 x 10 em).) [24]. The column was washed with 
washing buffer at pH 7.5, and a linear gradient of 0.2-0.5 M NaCI was applied . 
Porin containing fractions were detected and precipitated. Final resuspension 
was done in 10% d-actyl-glucoside (DOG) (Annatrace, Affymetrix, Santa Clara, 
CA, USA) with 10 mM Hepes, pH 7.2. Solubilized preparations were dialyzed 
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against 3 changes of PBS with 0.02% azide (>5 x 1010 times the original volume 
of the sample over 72 h) to remove the detergent [24]. During dialysis PorB forms 
lipid-free micelles known as proteosomes [11 0]; this preparation will be referred 
to as "PorB" from this point forward . Protein concentrations were measured using 
a BCA protein assay reagent kit (ThermoFisher Scientific, Waltham, MA, USA) 
as per the manufacturer's protocol. 
PorB activity was confirmed by stimulating HEK cells that had been stably 
transfected with a vector expressing TLR2, TLR4 or an empty vector [116] as has 
been described previously [117]. 5 x 105 cells were plated in each well of a 24 
well plate (Corning) and stimulated with 10 j.lg/ml PorB for 24 hours. Activity was 
measured as the ability to induce IL-6 in TLR2 transfected cells, but not those 
containing the empty vector or TLR4. IL-6 was measured from the supernatant 
using an ELISA kit (BD OptEIA, Becton Dickson) following the manufacturer's 
protocol. Pam3CS~ (lnvivogen) was used as a TLR2 positive control, N. 
meningitidis lipooligosaccharide (LOS) was used as a TLR4 positive control, and 
TN Fa (Sigma Aldrich) was used as a universal positive control. 
Ovalbumin was derived from chicken egg whites by freeze-drying followed 
by lyophilization and resuspension of the total protein in sterile PBS. 
Resuspended Ova was sterilized by passage through a 0.22 1-1m filter. Ova 
concentration was measured by the BCA assay as described above. Endotoxin 
contamination of Ova and PorB was monitored by silver staining of SDS-PAGE 
gels. Contamination was detected as ladder-pattern banding in PorB lanes 
33 
equivalent to endotoxin positive controls. E. coli LPS (Sigma-Aldrich) and N. 
meningitidis LOS were used as positive controls . 
Coomassie Staining 
Coomassie solution was made by mixing 45 ml dH20 with 45 ml methanol, 
10 ml acetic acid, and 0.25 g Coomassie Brilliant Blue (Sigma Aldrich). 
Sonication was used to solubilize the Coomassie dye, and the solution was 
passed through Whatman 3MM filter paper (Whatman, Middlesex, UK) to remove 
any particulates. SDS-PAGE gels were added to Coomassie solution and 
incubated at room temperature for at least 4 hours. The gel was then washed 
with changes of dHzO and de-stained with a solution of 25% propanol and 10 % 
acetic acid in dHzO until visible bands were clear. Gels were preserved by 
equilibrating in 4% glycerol and 10% ethanol, then dried on a frame (Owl 
Separation System, Portsmouth, NH) between two sheets of gel drying film 
(Promega, Madison, WI, USA). 
Silver Staining 
SDS-PAGE gels were placed in a well-cleaned glass petri dish containing 
50 ml of a 40% methanol, 10% acetic acid solution and allowed to equilibrate 
with gentle rocking at room temperature for 30 minutes. Gels were then washed 
twice for 15 minutes with a solution of 10% ethanol and 5% acetic acid. Silver 
stain oxidizer concentrate (Bio-Rad) was dilute 1:10 with ddHzO to a total volume 
of 20 ml, and incubated with the gel for 5 min. Gels were then washed 2 x 5 min 
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with ddH20 . Silver stain reagent (Bio-Rad) was diluted 1:10 with ddH20 to a total 
volume of 20 ml, and incubated with the gel for 20 min. Gels were then washed 
with ddH20 for 1 min. Developer solution was made immediately prior to use by 
mixing 5 g of silver stain developer (Bio-Rad) with 150 ml ddH20. Wash water 
was removed from the gels, and 25 ml developer solution was added. Once the 
developer solution turned cloudy, it was removed, and fresh developer added. 
This process was repeated until bands were clearly visible on the gels, and the 
reaction stopped by adding 25 ml of 5% acetic acid. Then gel was then 
· equilibrated in dH20 and then dried as described above for Coomassie gels. 
Antibody and chemokines assays 
Mouse sera were assayed for antigen-specific immunoglobulins by 
enzyme-linked immunosorbent assay (ELISA) as previously described [29]. 
lmmulon 2HB 96-well plates (Thermo Fisher) were coated with 100 1-11 Ova (5 
j..lg/ml) in coating buffer (0.2 M sodium carbonate in PBS, pH 9.4) and incubated 
overnight at 4 oc. Lanes for the standard curve were coated with 100 1-11 goat anti-
mouse F(ab)'2 (Sigma Aldritch) at 10 j..lg/ml under the same conditions. Plates 
were washed 3x with washing buffer (PBS + 0.05% Tween20 (ThermoFisher). 
200 1-11 blocking buffer (PBS + 5% BSA (Sigma Aldrich) + 0.05% Tween20) was 
added and plates were incubated for 1 h at 3TC, then washed as above. Sera 
were sequentially diluted in washing buffer starting at 1 :50 and added to the 
previously coated wells, and incubated overnight at 4 ·c. Standard curves were 
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generated using control mouse lgG (Sigma Aldrich) beginning at 800 ng/ml and 
diluted using serial dilutions down to 24 pg/ml. Plates were washed as above, 
then 100 1-11 of 1:10,000 dilution alkaline phosphatase-conjugated anti-mouse lgG 
(Sigma Aldrich), or 1:5,000 dilution anti-subtype lgG (Sigma Aldrich) were added. 
After 3 washes with washing buffer as above, the color was developed with 1 00 
1-11 one-step p-nitrophenyl phosphate (Pierce, Rockford , IL) for 15 min and the 
optical density (OD) at 405 nm was measured on an Elx800 reader (Bio-Tek 
Instruments, Inc., Winooski, VT). A standard curve was made using the 
colorimetric values obtained for total lgG control samples by plotting the average 
of each controllgG concentration, finding the linear portion of the curve on a log-
log transformed graph, and calculating the regression line over that range. The 
equation obtained for the regression line was then used to calculate the 
concentration of lgG in each sample. lgG subtypes were reported as the optical 
density (OD) of a 1 :50 dilution of serum in PBS. 
Generation of bone marrow derived macrophages (BMDM) 
BMDMs were generated from the femurs and tibias of C57BU6, TLR2 KO 
and My088 KO mice [118].[118]. Following the removal of muscle tissue, marrow 
was flushed from the bones with RPMI 1640 (Gibco, Life Technologies, 
Carlsbad , CA, USA). Single cell suspensions were generated by disruption using 
a 25G needle and passage through a 70 1-1m nylon mesh (ThermoFisher 
Scientific). Erythrocytes were removed with lysis buffer (0.15 M ammonium 
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chloride, 0.05 M potassium bicarbonate, 0.5 mM EDTA), washed in PBS, and the 
remaining cells pelleted, then plated in RPMI1640 supplemented with 10% FBS 
(Cellgro) , 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO, USA), 100 ~g/ml 
streptomycin (Sigma-Aldrich) and 20% 0.22 ~m-filtered L929 (a M-CSF secreting 
cell line) conditioned media. Cells were plated in 10 em bacterial plastic 
(ThermoFisher) plates. Media was changed every 3 days. Washing of the plates 
with PBS was used remove loosely attached and unattached cells, purified 
macrophage progenitor cells remained by adherence to the plastic. Before 
experiments cells were removed from the plates by washing with 0.05% trypsin 
and 0.53 mM EDTA (Cellgro) then seeded at the appropriate density. 
Removal of endotoxin protein contamination from LPS and LOS 
Lipoprotein contamination was removed from LPS and LOS samples 
using double phenol extraction, as has been previously described [119]. E. coli 
LPS (Sigma Aldrich) or N. meningitidis LOS (g ift of Mike Apicella) was 
resuspended in endotoxin-free water containing 0.2% triethylmine (TEA) (Sigma 
Aldrich). Deoxycholate (DOC) (Acros Organics, ThermoFisher Scientific) was 
added to a final concentration of 0.5%, followed by the addition of an equal 
volume of water-saturated phenol. Samples were vortexed intermittently for 5 
min, and the phases were allowed to separate at room temperature for 5 min. 
Samples were placed on ice for 5 min, followed by centrifugation at 4 ·c for 2 min 
at 10,000 x g. The top aqueous layer was transferred to a new tube and the 
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phenol phase was subjected tore-extraction with 500 1-11 of 0.2% TEA/0.5% DOC. 
The aqueous phases were pooled andre extracted as above with 1 ml of water-
saturated phenol. The pooled aqueous phases from the second extraction were 
adjusted to 75% ethanol and 30 mM sodium acetate (Sigma Aldrich) and allowed 
to precipitate at -2o·c for 1 h. The precipitates were centrifuged at 4 ·c to 10 min 
at 10,000 x g, washed with 1 ml of cold 100% ethanol, and air dried. The 
precipitates were resuspended in 500 1-11 of 0.2% TEA. 
BMDM Stimulation and IL-1 J3 measurement 
C57BL/6 BMDMs were seeded in 24-well plates (Corning) at 5 x 105 
cells/well. 24 hours later, selected wells were stimulated in triplicate with one of 
the following TLR ligands: E. coli LPS double extracted in phenol chloroform to 
remove lipoprotein contamination, (1 00 ng/ml) (Sigma-Aldrich) , Pam3CS~ (1 00 
ng/ml) (lnvivogen, San Diego, CA, USA) or N. meningitidis porin PorB (1 0 1-Jg/ml). 
5 hours after stimulation, selected wells were stimulated with 5 mM ATP for 30 
minutes. After 30 minutes, all supernatants were harvested and analyzed with 
the mouse IL-1~/IL-1F2 ELISA kit (R&D Systems)) using amodified protocol. 
lmmulon 2HB plates (Thermo Fisher) were coated overnight with 100 1-11 of 4 
1-Jg/ml of rat anti-mouse IL-1 ~(R&D Systems). Plates were washed 3x with PBS 
and wells were blocked with PBS for 1 hour at room temperature. Plates were 
washed and 2001-11 of known concentrations of recombinant IL-1~ (R&D 
Systems) or 1:2 dilutions of supernatant in PBS were added to the coated wells 
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for 2 hours at 37°C. Plates were washed and 100 IJI of 2.5 IJg/ml biotinylated goat 
anti-mouse IL-1 ~(R&D Systems) was added to the wells. Plates were washed 3x 
with PBS and 100 IJI streptavidin-HRP (R&D Systems) was added to the wells, 
then incubated for 1 h at 37°C. After washing the plates 3x in PBS, 100 IJI of a 
1:1 mixture of H202 and TMB (R&D Systems) was added as a substrate for 20 
minutes at room temperature. Absorbencies were read at 450 nm as above. IL-
1 ~ concentrations in the standard curve were used to calculate a regression line 
from the linear portion of the graph. The linear regression line was used to 
calculate the concentration of IL-1 ~in each supernatant sample. 
Generation of bone marrow dendritic cells (BMDC) 
BMDCs were generated from the femurs and C57BU6, TLR2 KO and 
MyD88 KO mice as has been previously described [90, 118, 120]. Cells were 
isolated as above for BMDMs, but plated into 24 well plates (Gibco) in media 
containing 10% FBS (Cellgro), 20 ng/ml rGM-CSF (Sigma Aldrich), 50 1Jm 2-ME 
(Gibco), and 201Jg/ml gentamycin (Sigma Aldrich). Cells were seeded at 5 x 105 
cells I mi. 700 IJI of media was removed every 2 days, and replaced with fresh 
media containing rGM-CSF. On day 4, cells were split 2:1 and re-seeded in 24 
well plates. Experiments were begun on day 6 without further re-seeding of the 
cells, to avoid additional handling and incidental activation of the DCs. 
Cell Stimulation and Antigen Uptake 
39 
C57BL/6, TLR2 KO, and MyD88 KO BMDMs were seeded in 24-well 
plates (Corning) at 2 x 1 as cells/well. 24 hours later, ovalbumin purchased with 
an Alexa-594 label attached (Molecular Probes, Life Technologies, Carlsbad, CA, 
USA) was added to the wells at 5 IJg/ml. At this time, the cells were also 
stimulated with one of the following TLR ligands: E. coli LPS double extracted in 
phenol chloroform to remove lipoprotein contamination , (1 aa ng/ml) (Sigma-
Aldrich) , Pam3CSK4 (1 aa ng/ml) (lnvivogen, San Diego, CA, USA) or N. 
meningitidis porin PorB (1 a IJg/ml).). Cells were allowed to rest for 2, 4, 6, or 24 
hours. Cells were detached with 2aa IJI of 4 mg/ml lidocaine HCI (Sigma) and 1 a 
mM EDTA for 1a min at room temperature, followed by gentle scraping. Cells 
were washed twice in PBS and examined by flow cytometry. For fluorescent 
microscopy, cells were grown as above, but plated onto Lab-Tekll chamber 
slides (Nalge Nunc, Naperville, IL, USA) at 1 x 1 as cells/well. Cells were 
stimulated for 6 hours with 1 a IJg/ml Alexa-594 labeled Ova (Ova-A594) and the 
indicated TLR agonist or media controls. After stimulation, slides were washed 3 
times with PBS and dehydrated with 2 washes of 95% ethanol and 2 washes of 
1 a a% ethanol. Two final washes were performed in xylenes, anti-fade mounting 
media (SiowFade with DAPI, Invitrogen) was added , and a coverslip (Corning, 
Corning, NY, USA) was placed over the slide. Slide corners were fixed with nail 
polish. Slides were stored at 4 ·c and covered until ready for use. 
Dendritic cell antigen uptake experiments were performed as above, with 
the exceptions that DCs were not re-seeded at a lower density prior to 
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stimulation. Additionally cells were dislodged with vigorous pipetting prior staining 
with anti-CD11c PE (Becton Dickinson) for flow cytometry. 
Fluorescent Microscopy 
All fluorescent microscopy images were obtained on a Nikon 
deconvolution wide-field Epifluorescence system (Nikon, Tokyo, Japan) with a 
mercury-halide light source. Filters sets used were UV excitation/blue emission 
for DAPI, yellow-green excitation/red emission for Alexa-594. Images were 
captured using 40x and 60x oil immersion objectives. All images were captured 
using NIS Elements (Nikon) and analyzed using lmageJ (NIH). For absolute 
intensity comparisons, 14 IJS exposures were used, based on the optimal 
exposure for the brightest samples. For high resolution and deconvolution 
imaging auto-exposure settings were used. Z-stacks for deconvolution were 
obtained by bracketing the in-focus region of the monolayer and applying 300 nm 
spacing to the slices. At least 1 0 slices were obtained for each sample. 
Deblurring was performed using the Parallel Iterative Deconvolution plug-in for 
lmageJ on a 16-core workstation with 32GB of RAM . Theoretical Point Spread 
Functions (PSF) were generated using the Diffraction PSF 3D plugin, using the 
appropriate settings for each z-stack. Deconvolution was done using the 3D 
spatially invariant method and the pre-set parameters of the plug in. 
Hock Vaccinations 
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A hock vaccination model to examine recruitment to draining lymph nodes 
[121] was used under the advisory of the BU IACUC. Briefly, mice were gently 
restrained, and a 31 G needle used to inject 10 IJI of the designated vaccine into 
the lateral aspect of the ankle, avoiding all major blood vessels. Half of the mice 
were vaccinated with PBS in one ankle and 5 IJg Ova-A594 in the second. The 
other half of the mice were vaccinated with 5 IJg Ova-A594 in one ankle and 1 0 
IJg PorB + 5 IJg Ova-A594 in the second. This allowed the contralateral ankle of 
each mouse to be used as an internal control, while also controlling for systemic 
versus localized effects of including PorB as an adjuvant. 
Lymph Node Preparation 
24 hours after hock vaccinations, mice were C02 euthanized, and the 
draining popliteal lymph nodes (LNs) removed by dissection. LNs were torn with 
tweezers and digested using 30 IJI Collagenase D (ThermoFisher) in 1 ml PBS 
with Ca++ and Mg++ for 30 minutes at 37° C with gentle agitation to allow for 
easier separation of dendritic cells. A single cell suspension was generated by 
grinding the remaining tissue using a 70 IJm nylon mesh (ThermoFisher). Cells 
were washed in PBS, counted, and stained as above for analysis using flow 
cytometry. 
Sectioning for Fluorescent Microscopy 
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For fluorescent microscopy, mice were given hock vaccinations as 
described above. 24 hours post injection mice were euthanized, and the draining 
popliteal LNs removed by dissection. Nodes were embedded in Optimal Cutting 
Temperature (OCT) medium (Richard Allan Scientific, Kalamazoo, Ml, USA) in 
molds (ThermoFisher) and flash frozen in an ethanol and dry ice mixture. 
Prepared nodes were stored at -80°C until ready for use. Sectioning was 
performed on a cryostat (Microm HM 550, Microm International GmbH, Walldorf, 
Germany). Blocks containing nodes were removed from molds and placed on 
mounts with a drop of OCT medium, which was allowed to freeze while the 
blocks equilibrated to the -2o·c internal temperature of the-cryostat. 20 IJm slices 
were made until the node was visible at the surface of the block. 8 IJm sections 
were obtained, and placed on lysine treated slides (Colorfrost Plus, 
ThermoFisher). Sections were air dried at room temperature for 1 hour, then 
fixed in acetone at -2o·c for 8 minutes. Sections were dehydrated in successive 
ethanol baths of 2 x 5 minutes in 95% ethanol, followed by 2 x 5 minutes in 100% 
ethanol. Dehydrated sections were washed with 2 x 5 minute baths in xylenes, 
then mounted and counterstained in medium containing DAPI (SiowFade with 
DAPI, Invitrogen). Light microscopy was performed on a widefield epifluorescent 
microscope as described above. 
Flow Cytometry 
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Flow cytometry [122] was conducted on a BD LSRII flow cytometer 
(Beckton Dickinson Biosciences, San Jose, CA). In brief, cells were harvested 
with gentle scraping and transferred to F ACS tubes (Becton Dickinson 
Biosciences, San Jose, CA). Cells were washed with cold FACS buffer (0.2% 
BSA + 0.01% sodium azide in PBS) then stained for 30 minutes on ice with 0.5 
~g of the indicated fluorescently labeled antibody in 150 ~I of cold buffer. 
Analysis was performed in FlowJo (Tree Star, Ashland, OR, USA). Antibodies 
used:: FITC or PE rat lgG2a, FITC anti-lAb, PE anti-CD11 b, FITC or PE anti-
CD11c, FITC anti-CD14, FITC anti-CD54, FITC or PE anti-CD40, FITC anti-
CD69, FITC or PE anti-CD86, FITC anti-TLR2, and FITC anti-TLR4 (Beckton 
Dickinson Biosciences, San Jose, CA and Caltag, Burlingame, CA). Forward and 
side scatter gates were used to identify live cells. 
Vaccinations for microarray experiments 
Mice to be used in microarray studies were vaccinated on a 3 x 2 week 
schedule as described above. For the preliminary microarray experiment, 
C57BLI6 mice were separated into groups of three for each vaccine formulation. 
The formulations were 1 0 ~g Ova, 1 0 ~g PorB, 10 ~g Ova + 1 0 ~g PorB, or mock 
vaccinated with PBS only. All vaccines were delivered in 100 ~I of PBS 
subcutaneously behind the neck. 24 hours after the third vaccination, mice were 
sacrificed and their spleens removed. Spleens were immersed in 1 ml RNA/ater 
(Qiagen, Venlo, Netherlands) to preserve RNA content. RNA was extracted using 
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RNEasy kits (Qiagen) according to the manufacturer's instructions. 
Approximately one third of the spleen (-20 mg) was diced with sterilized scissors 
and then disrupted using a tissue homogenizer (PRO Scientific, Oxford, CT, US) 
for the initial processing steps. RNA collected from each sample was purified and 
stored at -ao·c until all samples were collected. Purified RNA was checked for 
quality and concentration on a Nanodrop system (Thermo Fisher Scientific) to 
insure that all samples met the Microarray Core's minimum requirements for 
concentration and purity. Purified RNA was delivered to the Boston University 
School of Medicine (BUSM) Microarray Core for reverse transcription and 
analysis on Affymetrix Mouse Gene 1.0 microarray chips (Affymetrix, Santa 
Clara, CA, US). On delivery of the RNA to the Core, each sample was assayed 
using an Agilent Bioanalyzer to obtain a more detailed analysis of its 
composition. All of the samples were determined to meet the standards of the 
Core. Data analysis was performed in cooperation with an in-house 
bioinformaticist. 
For the second microarray experiment, mice were divided into sample 
groups by number of injections and vaccine formulation received, resulting in a 
total of 10 different conditions. C57BL/6 mice were given 1, 2 or 3 injections of a 
vaccine formulation spaced 2 weeks apart. Formulations were 10 IJg Ova, 10 IJg 
PorB or 10 IJg Ova + 10 IJg PorB. Control mice were given three injections of 
PBS only. All vaccines were delivered in 100 IJI of PBS subcutaneously behind 
the neck. 24 hours after the indicated number of vaccinations, mice were 
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sacrificed and spleens collected. To avoid any effects of RNA/atertreatment, 
spleens were immediately processed for RNA purification using RNEasy kits as 
described above. Terminal exsanguination via cardiac puncture was also 
performed. Serum was purified using BD Microtainer serum separator tubes 
(Becton Dickinson). RNA was delivered to the BUSM Microarray core for analysis 
as described above. 
Microarray Analysis 
Statistical analysis of the first microarray experiment was conducted in 
collaboration with the BUSM Microarray core. Statistical analysis of the second 
microarray experiment was performed in collaboration with Adam Gower of the 
Clinical and Translational Science Institute (CTSI) of BUSM. Raw Affymetrix CEL 
files were normalized to produce gene-level expression values using the 
implementation of the Robust Multiarray Average (RMA) [123] in the "affy" 
package [124] included within in the Bioconductor software suite (version 2.1 0.0) 
[125] and an Entrez Gene-specific probeset mapping from BrainArray (version 
14.0.0) [126, 127]. Empirical Bayesian (moderated) ttests and linear modeling 
were performed using the limma package [128], and analyses of variance 
(ANOVAs) were performed using the sva package [129]. Correction for multiple 
hypothesis testing was accomplished using the Benjamini-Hochberg false 
discovery rate (FOR) [130]. Unbiased clustering analysis was performed to group 
samples by similarity of expression profiles. All statistical analyses were 
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same human Entrez Gene identifier were collapsed into a single value by 
averaging. After trimming genes with no human homologs and collapsing 
repeated genes 16,000 human gene IDs were left in each ranked file. GSEA 
software from the Broad was used for all analyses. Ranked lists were probed 
against the collected gene sets from Biocarta, Reactome and KEGG. This 
generated an initial list of -2,800 gene sets. Parameters were set in GSEA 
according to the suggested guidelines to exclude any gene set with fewer than 
15 or more than 500 genes represented in the gene lists, leaving -2,000 sets. A 
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random seed was generated for each analysis, and all experiments were done 
with 1,000 repetitions. 
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Results 
Chapter 1: TLR2 and MyD88 dependency of PorB immune activation and 
adjuvant activity 
Our lab and others have previously demonstrated that PorB stimulates the 
innate immune system and acts as an adjuvant. We have also shown that PorB 
activates TLR2 [2] and induces pro-inflammatory signaling pathways in a TLR2 
and MyD88 mediated manner [90]. We were interested, therefore, in determining 
I 
the extent to which inflammatory processes in response to PorB, and the 
adjuvant activity of PorB, were dependent on intact TLR2 and MyD88 signaling. I 
investigated the ability of PorB to increase cell surface protein expression in 
macrophages using TLR2 KO cells. To test for overall adjuvant activity, I 
I 
vaccinated TLR2 and MyD88 knockout mice with Ova with or without PorB to 
determine the extent of adjuvanticity conveyed by PorB in the absence of each 
gene. 
Cell surface markers are upregulated on BMDMs following stimulation with 
PorB 
Expression of cell surface proteins on APCs is both a measure of 
activation and, in cooperation with T cells, a mechanism of communication 
between the innate and adaptive arms of the immune system [1 09, 135]. We 
examined proteins associated with T cell stimulation, (CD40, CD86)) [136-138] 
and for APC motility (CD54) [135, 139], as well as other markers of BMDM 
activation (CD14, and CD69) [1 09].[1 09]. We have previously shown that PorB 
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induces upregulation of CD86 and MHCII on APCs, but not CD80 [30]. BMDMs 
from C578U6 or TLR2 KO mice were stimulated with PorB, or Pam3CSK.t or 
LOS as positive controls, for 24 hours, then stained for surface proteins and 
analyzed by flow cytometry. All five cell surface proteins were upregulated by 
PorB in cells from WT mice. CD14, CD40 and CD86 were not upregulated in 
cells from TLR2 KO mice following PorB stimulation, relative to unstimulated cells 
from TLR2 KO mice (Fig. 1). Unexpectedly, CD54 and CD69 were partially 
upregulated in cells from TLR2 KO mice following stimulation with PorB. All five 
markers were expressed at baseline in TLR2 KO cells stimulated with 
Pam3CSK.t. All five molecules were upregulated in BMDMs from WT mice 
following stimulation with the TLR4 ligand LOS. LOS induced upregulation 
remained constant in cells from TLR2 KOKO mice. 
Upregulation of CD14, CD40, CD54, CD69 and CD86 indicates that 
stimulation with PorB places macrophages in an activated state from which they 
would be well positioned recruit antigen-specific T cells and engage the adaptive 
immune system. Loss of CD14, CD40 and CD86 up-regulation in response to 
PorB in TLR2 KO cells demonstrates that TLR2 is essential in these signaling 
pathways, and may play a role in the partial loss of adjuvant activity by PorB 
observed in TLR2 KO mice below. That CD54 and CD69 were still partially 
upregulated by PorB in TLR2 KO cells, even when Pam3CSK.t induced 
upregutation was entirely ablated, implies that PorB may act partially through a 
TLR2 independent pathway. This finding may be related to the observation below 
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that PorB still retains some measure of adjuvant activity even in TLR2 KO mice in 
vivo. 
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Figure 1: Upregulation of co-stimulatory cell-surface proteins by PorB is 
partially TLR2 dependent. BMDMs from WT or TLR2 KO mice were stimulated 
in culture with PorB, Pam3CSK4 or LOS, then stained for markers of activation 
and examined by flow cytometry. In WT cells, PorB increased surface expression 
of CD14, CD40, CD54, CD69 and CD86 as compared to unstimulated cells. 
Knockout cells had decreased expression of CD14, CD40 and CD86, but still had 
higher expression of CD54 and CD69 when compared to basal levels. In the 
latter two cases, the TLR2 ligand Pam3CSK4 had no effect on TLR2 KO cells. 
Histograms are from one representative sample of at least 3. Data represents 
one of two experiments. 
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Stimulation of cells by TLR ligands may induce increase expression in the 
cell of the cognate receptor to the ligand [9, 140]. To investigate the possibility 
that PorB creates such a positive feedback loop, we determined if there was 
increased surface expression of TLR2 and/or TLR4 on BMDMs following 
stimulation with PorB or LOS. Cells were stimulated with 10 !Jg/ml PorB or 100 
ng/ml LOS as above in vitro for 24 hours and then assayed by flow cytometry. 
Stimulation with either PorB or LOS led to increased surface expression of TLR2 
as compared to unstimulated controls; neither ligand increased surface 
expression of TLR4 (Fig. 2). This demonstrates that stimulation of innate immune 
cells with PorB has the potential to include a positive feedback loop specific for 
TLR2. Establishment of a positive feedback loop would aid. in robust activation of 
the innate immune system, a desired feature in a vaccine adjuvant. 
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Figure 2: PorB increases surface expression of TLR2. C57BI/6 mouse 
BMDMs were stimulated with PorB or LOS. Stimulation lead to increased surface 
expression of TLR2 following stimulation with either TLR ligand when compared 
to media controls. Neither ligand, however, induced surface expression of TLR4. 
Histograms are from one representative sample of at least 3. Data represents 
one of two experiments. 
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PorB alone is not sufficient to activate the inflammasome 
Activation of the inflammasome is a potential mechanism of action for 
adjuvants that is of significant interest [85 , 141]. It is also a pathway known to be 
My088 dependent [142]. Stimulation with PorB was investigated to determine if 
PorB alone was sufficient to activate the inflammasome in vitro. Release of 
cleaved IL-1 ~requires activation of both signals for the inflammasome: increased 
pro-IL-1~ synthesis and cleavage of pro-IL-1~ by activated Caspase 1 [141]. 
C57BL/6 BMDMs were stimulated with PorB, LPS or Pam3CSK4. After 5 hours, 
exogenous A TP was added to half of the wells to trigger activation of Caspase 1 
[142]. In the absence of ATP, none of the TLR ligands stimulated the release of 
IL-1~ as measured by ELISA. However, increased mature IL-1~ following ATP 
co-stimulation was observed for all of the TLR ligands tested including PorB 
(p<0.05) (Fig. 3) . Failure to observe mature IL-1~ release after stimulation with 
PorB alone indicates that activation of the inflammasome likely does not play a 
sign ificant role in the adjuvant activity of PorB. 
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Figure 3: PorB stimulates IL-113 release only in the presence of ATP. WT 
BMDMs were stimulated with PorB, LPS, TN Fa, or Pam3CS~ at the indicated 
concentrations for 5 hours. After 5 hours, ATP was added to half the cells for 30 
minutes. Supernatants were collected and analyzed by IL-1~ ELISA. IL-1~ 
release was not observed for PorB, LPS or Pam3CSK4 in the absence of ATP. In 
the presence of ATP, significantly increased IL-1~ release was observed for all 
three TLR ligands (p<0.05). Data is representative of two independent 
experiments. 
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MyD88 and TLR2 are necessary for the maximal adaptive immune response 
to PorB 
Previous work by our lab has shown that PorB is a TLR2 agonist [2], and 
that it functions as an adjuvant in vaccines [26]. We were interested in 
demonstrating that this adjuvant effect was dependent on intact TLR2 and 
MyD88. Previous research had shown that many immune stimulating functions of 
PorB were dependent on TLR2 and MyD88, but we had yet to conclusively 
demonstrate that signaling through these proteins is essential for overall 
adjuvanticity. To determine whether TLR2, or its downstream adapter protein 
MyD88, are required for the adjuvant activity of PorB, mice lacking either gene 
were vaccinated and antigen-specific antibody production was measured. TLR2 
KO or MyD88 KO mice, in addition to WT C57BL/6 mice, were vaccinated with 
10 IJg Ova or a combination of 10 IJg Ova + 10 IJg PorB. Vaccines were 
administered subcutaneously (s.c.) on days 0, 14, and 28. The level of the 
humoral immune response generated towards the antigen (Ova) was then 
determined. Blood was collected from the mice on day 42, and the serum 
assayed by ELISA for Ova-specific lgG. Consistent with previous work, WT mice 
had significantly higher concentrations of Ova-specific lgGwhen vaccinated with 
Ova + PorB as compared to Ova alone (p<0.001) as determined by a two-tailed 
Mann-Whitney test, used due to the non-parametric distribution of lgG titers. 
TLR2 KO mice vaccinated with Ova + PorB had significantly lower concentrations 
of Ova-specific lgG than WT mice given the same vaccine, but higher levels of 
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lgG than TLR2 KO mice vaccinated with Ova alone (p<0.05). (Fig. 4a). For all 
mice, anti-Ova lgG in pre-immune sera was below the limit of detection (data not 
shown). Despite the slight retention in adjuvanticity of PorB in the TLR2 KO mice, 
the substantial decrease in lgG from the WT mouse model demonstrates the 
importance of TLR2 signaling to the adjuvant effects of PorB. It is also not clear if 
the small increase in antibody levels observed after vaccination with PorB as an 
adjuvant in TLR2 KO mice would correspond to any protective effect were these 
experiments repeated in a challenge model. In contrast, MyD88 KO mice 
vaccinated with Ova showed no increase in the level of Ova-specific lgG when 
PorB was added to the vaccine formulation. This demonstrates that intact MyD88 
signaling is essential for the adjuvant activity of PorB, confirming the initial 
hypothesis. Taken together with the results of the TLR2 KO vaccinations, these 
data suggest that PorB may poses some TLR2 independent, MyD88 dependent, 
adjuvant activity that has not previously been reported. 
We further investigated the dependence of the adjuvant activity of PorB on 
TLR2 to determine if it would be similar for the individual lgG subtypes. 
Subtyping lgG can additionally be used to characterize the immune response to 
PorB as a marker of potential skewing of the response towards a Th1 or Th2 
phenotype [143]. The relative amount of OVA specific lgG1, lgG2b, lgG2c and 
lgG3 was determined in sera obtained from vaccinated mice two weeks after the 
third immunization (Day 42). The OD at a single, fixed dilution of 1 :50 was 
determined as quantitation of lgG subtypes could not be performed in the 
58 
absence of suitable purified lgG subtype standards. WT mice vaccinated with 
Ova+ PorB demonstrated an immune response dominated by lgG1 and lgG2b 
(Fig. 4b). These subtypes, in turn, were significantly suppressed in the 
responses of TLR2 KO mice given the same vaccine. lgG11gG1 and lgG2b are 
both associated with a Th2 type response [144]. As both subtypes decreased in 
expression in TLR2 KO mice vaccinated with PorB as compared to WT mice 
administered the same vaccine formulation, it can be concluded that both the 
adjuvant activity of PorB and the T helper phenotype of the response it induces 
are dependent on TLR2-mediated processes. Interestingly, immunization of 
TLR2 KO mice resulted in a statistically significant (p<0.05) increase in lgG2c 
production as compared to WT mice, possibly indicating that the non-TLR2 
mediated adjuvant activity of PorB may skew more towards a Th1 type response, 
as lgG2c induction is related to production ofTh1 type cytokines (i.e. IL-12) 
[145]. However, the biological relevance of the phenomena is currently unclear. 
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Figure 4: Increases in antigen-specific lgG by PorB is dependent on TLR2 
and MyD88. (a) Concentration of lgG antibody to Ova in C57BI/6 mice as 
measured by ELISA in serum on from day 42. WT C57BI/6, TLR2 KO and My088 
KO mice were vaccinated on days 0, 14 and 28 with Ova, Ova+ PorB or sham 
(PBS). Vaccines that included PorB showed significantly less elevation in lgG 
over vaccines that did not include PorB in TLR2 KO mice, and no detectable 
effect in My088 KO mice. None of the mice had detectable antibodies to Ova 
prior to vaccination (data not shown). (b) 00 of specific subtypes of anti-Ova lgG 
at a 1:50 dilution of serum as measured by ELISA. In WT mice, lgG1 and lgG2b 
were the dominant subtypes indicative of a Th2-type response. These in turn 
decreased in the TLR2 KO mice, consistent with the total lgG data. n=4, data 
represents one of two experiments. 
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Chapter 1: Conclusions 
In summary, I set out for this first Aim to characterize aspects of the 
immune stimulating activity of PorB and the reliance of these effects on intact 
TLR2 and My088 signaling. Evidence of increased cell surface expression of 
proteins in response to stimulus with PorB was expanded to include 
macrophages, as has been previously been demonstrated for dendritic cells [90] 
and B cells [33]. In contrast, it was discovered that stimulus with PorB alone is 
not sufficient to induce release of mature IL-1~. Surprisingly, while previous work 
in our lab has demonstrated that TLR2 is required for signaling in response to 
stimulus with PorB, it was observed that expression of CD54 and CD69 was still 
increased in response to stimulus with PorB in macrophages derived from TLR2 
KO mice. This response to stimulation with PorB in the absence of its canonical 
receptor demonstrates that more of the molecular biology of PorB's interactions 
with the immune system have yet to be elucidated. 
One of the goals of this research is to better understand the activity of 
PorB as a vaccine adjuvant. As discussed above, the responses of purified 
immune cell types to stimulation with PorB has been studied for dependence on 
intact TLR2 and MyD88. To expand these results to the use of PorB as an 
adjuvant, I examined the adaptive immune response in mice lacking TLR2 or 
MyD88 following vaccination with PorB as an adjuvant, and found that the loss of 
TLR2 significantly decreased the adjuvant effect of PorB, while the loss of 
MyD88 entirely ablated it. The presence of any adjuvant effect of PorB in the 
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absence of TLR2 was unexpected, and reinforces the conclusion reached from 
the observation of increased surface protein expression in cells derived from 
TLR2 KO mice, that significant questions about the immune stimulating effects of 
PorB remain to be answered. 
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Chapter 2: PorB induced antigen uptake and APC migration 
Antigen uptake, processing and presentation have long been recognized 
as a key series of events in the communication between the innate and adaptive 
immune systems. Various TLR ligands have previously been shown to increase 
activity through these pathways, and this has been hypothesized to play a role in 
their ability to act as vaccine adjuvants. Given these reports, we were interested 
in determining if PorB was also capable of interacting with antigen handling. If so, 
indicate another pathway that could plausibly explain some of the adjuvant 
activity of PorB. To this end, I investigated a number of the early events in 
antigen presentation by APCs, including antigen uptake and migration of APCs 
from the periphery to the draining lymph nodes. 
PorB increases antigen uptake in vitro at earlier time points than alternative 
TLR ligands 
The effect of PorB on antigen uptake and APC trafficking was examined, 
as this could be directly related to the PorB adjuvant activity we have previously 
described. Increased antigen uptake and processing has been attributed to other 
TLR ligands [75, 76]. If the same effects could be observed for the nano-scale 
particles formed by PorB [24] then this could play a role in enhancing 
presentation by the innate immune system and subsequent activation of adaptive 
immunity during vaccination. A fluorescently tagged version of the same antigen 
used in vaccination experiments was chosen to allow for ease of comparison 
between in vivo and in vitro experiments. Alexa-594 has the advantage of being 
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stable to long-term light exposure as well as easily differentiated from the 
common fluorescent tags (FITC, PE, APC) used in FACS. 
BMDMs from WT C57BU6 mice were seeded in tissue culture wells and 
stimulated with Alexa-594 labeled Ovalbumin alone or in the presence of PorB on 
control TLR ligands. Pam3CS~ was used as a TLR2-TLR1TLR1 heterodimer 
control, and E. coli LPS as a TLR4 control. In cells stimulated with Ova-A594 
alone essentially 1 00% of BMDMs demonstrated fluorescence above 
background; change in geometric mean intensity (GMI) was therefore used to 
interpret the effects of TLR ligand co-stimulation. At 2, 4 and 6 hours after 
stimulation, cells stimulated with Ova-A594 plus PorB demonstrated significantly 
(p<0.05) higher Ova uptake than cells stimulated with Ova alone or Ova in 
combination with LPS or PAM3CS~ (Fig. 5). At 2, 4 and 6 hours, LPS and 
PAM3CS~ had no significant effect on Ova uptake. At 24 hours after stimulation, 
WT cells treated with any of the three TLR ligands had equivalent GMI under the 
same conditions. The Mann-Whitney test was used for all statistical analyses due 
to the non-normal distribution of data. 
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Figure 5: Stimulation of murine BMDMs with PorB increases early uptake of 
antigen in vitro. A) Geometric Mean Intensity (GMI) of the Alexa-594 signal from 
BMDMs stimulated with Ova-A594 and the indicated TLR ligand, for 2, 4, 6 or 24 
hours. At 2, 4, and 6 hours, cells stimulated with PorB took up more Ova than 
cells stimulated with Ova alone or either LPS or Pam3CSK4. At 24 hours, cells 
stimulated with any of the TLR ligands had taken up equivalent levels of Ova-
A594, and were all higher than cells given Ova alone. B) PorB driven antigen 
uptake in a TLR2 dependent and MyD88 independent manner. BMDMs derived 
from TLR2 KO mice show less uptake of Ova after 6 hours in the presence of 
PorB than WT-derived BMDMs under the same conditions. Conversely, BMDMs 
derived from MyD88 KO mice and stimulated with PorB for 6 hours demonstrate 
equivalent Ova-A594 uptake to WT BMDMs also stimulated with PorB. * p<0.05 
n=4 data represents one of three experiments. 
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1 next hypothesized that the increase in antigen uptake in response to 
PorB stimulation was dependent on TLR2 and MyD88. Previous work with these 
knockout lines has shown that intact TLR2 and MyD88 signaling are required for 
other PorB-driven inflammatory processes, including upregulation of cell surface 
proteins and secretion of cytokines [25, 90]. The above experiments were 
therefore repeated using macrophages derived from TLR2 KO or MyD88 KO 
mice. Loss of PorB driven increases in antigen uptake in these cells would 
indicate that the knocked out protein played a role in this process. As it has been 
shown above that both of these proteins were required for the full adjuvanticity of 
PorB, loss of increased antigen uptake in either knockout line could imply that 
increased antigen uptake may play a role in the adjuvant effects of PorB. 
In BMDMs derived from TLR2 knockout mice PorB did not increase 
antigen uptake (Fig. 6). At 2, 4 and 6 hours post stimulation, there was no 
significant difference in antigen uptake between TLR2 KO BMDMs stimulated 
with Ova-A594 alone and cells co-stimulated with PorB, Pam3CS~, or LPS. After 
24 hours of stimulation there was no significant difference in antigen uptake 
between BMDMs stimulated with Ova-A594 alone and cells co-stimulated with 
PorB or Pam3CS~. Across all time points, ANOVA comparison of cells 
stimulated with Ova alone and in conjunction with PorB showed no significant 
difference (p>0.05) in Ova-A594 uptake. Cells stimulated for 24 hours with the 
TLR41igand LPS, however, showed increased Ova-A594 uptake as compared to 
cells stimulated with Ova alone. As both PorB and Pam3CS~ are TLR2 ligands, 
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this confirms a role for TLR2 in the observation that PorB increases antigen 
uptake. Moreover TLR2 appears to be essential for both the rapid antigen uptake 
driven by PorB and the slower antigen uptake observed in co-stimulation with 
Pam3CS~. This effect is receptor specific, as loss of TLR2 had no effect on the 
TLR4 ligand LPS. 
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Figure 6: Antigen uptake in TLR2 KO BMDMs. Macrophages derived from 
TLR2 KO mice were stimulated with Ova-Aiexa594 with or without the presence 
of TLR ligands PorB, Pam3CS~, and LPS. After 2, 4 or 6 hours post stimulation, 
none of the TLR ligands had a significant effect on antigen uptake in the BMDMs 
as measured by flow cytometry. After 24 hours of stimulation, only macrophages 
co-stimulated with the TLR4 ligand LPS showed an increase in antigen uptake 
above macrophages stimulated with Ova-A594 alone. ANOVA analysis of all time 
points reveals no significant effect (p>0.05) of co-stimulation with PorB or 
Pam3CS~. *: p<0.05 for Ova + LPS, n=4 data represents one of two 
experiments. 
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MyD88 is a key downstream mediator for the TLR2 signaling pathway, 
and the loss of MyD88 has ablated all signaling, inflammatory and adjuvant 
functions of PorB in which it has been studied to date [25, 90, 146]. As such , 1 
hypothesized that the loss of MyD88 would entirely ablate the increased antigen 
uptake by BMDMs observed in the presence of PorB. When this hypothesis was 
tested, however, the loss of MyD88 showed no effect on increased antigen 
uptake when BMDMs were stimulated with PorB, Pam3CS~ or LPS (Fig. 7). In 
parallel with results in cells derived from WT mice, at 2, 4 and 6 hours, cells 
stimulated with PorB showed increased Ova-A594 uptake as compared to cells 
stimulated with Ova alone. After 24 hours, cells stimulated with PorB, Pam3CS~ 
or LPS all showed increased Ova-A594 uptake as compared to cells stimulated 
with Ova alone. ANOVA analysis comparing cells stimulated with Ova alone and 
cells stimulated with PorB confirms a significant increase (p<0.05) in Ova-A594 
uptake across all time points. 
Contrary to the initial hypothesis, MyD88 does not appear to play a role in 
mediating the increase in antigen uptake by BMDMs observed in the presence of 
PorB. Taken together with the results using cells derived TLR2 KO mice (Fig. 
5b) , I propose a TLR2-dependent, MyD88-independent effect of PorB. This 
pattern of regulation has not previously been reported for any activity of PorB. On 
hypothesis that could explain these effects would rest on the particulate nature of 
PorB proteosomes, whereby interaction of multiple PorB epitopes on the surface 
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of the cell, combined with particle recogn ition effects [147] is sufficient to induce 
antigen uptake. 
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Figure 7: Antigen uptake in MyD88 KO BMDMs. Macrophages derived from 
MyD88 KO mice were stimulated with Ova-Aiexa594 with or without the presence 
of TLR ligands PorB, Pam3CSK.t, or LPS. ANOVA analysis of all time points 
confirms that cells co-stimulated with PorB take up significantly (p<0.05) more 
Ova-A594 than cells stimulated with Ova alone. By 24 hours, stimulation with all 
TLR ligands is sufficient to increase Ova-A594 uptake over stimulation with Ova 
alone. *: p<0.05, n=4, data represents one of two experiments. 
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PorB drives a significantly increased fraction of BMDCs to take up antigen 
During vaccination, dendritic cells play a key role in antigen trafficking and 
presentation toT lymphocytes [51, 57]. Given the finding that PorB increases 
antigen uptake in macrophages, I hypothesized that our observations of antigen 
uptake in macrophages would be replicated in dendritic cells as well. Dendritic 
cells were stimulated in vitro under the same conditions as macrophages. As the 
differentiation process did not induce 100% CD11 c positive cells , all samples 
were co-stained with hamster anti-mouse CD11 c PE to gate on DCs. In contrast 
with the results we observed experimenting with macrophages, not all of the DCs 
took up the antigen, as determined by flow cytometry. For this reason, changes 
in the uptake of antigen were measured as an increase the fraction of Ova-A594 
positive, CD11 c positive cells (Fig. 8). The effects of stimulation with TLR ligands 
were therefore defined as samples for which a higher fraction of DCs were 
antigen positive as compared to cells given Ova-A594 alone for the same period 
of time. 
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Figure 8: PorB increases the fractions of DCs positive for Ova-A594, 
but not the quantity of Ova taken up into the cell. Dendritic cells were 
stimulated with Alexa-595 labeled Ova in the presence or absence of PorB. After 
6 hours, cells were harvested, stained with a CD 11 c and examined by flow 
cytometry. A) Control cells mock stimulated with PBS, showing 68% of cells are 
CD11c positive. B) DCs (gated on CD11c+ cells) stimulated with 5 IJg/ml Ova-
A594. C) DCs stimulated with 5 IJg/ml Ova-A594 + 10 IJg/ml PorB. 62% of cells 
are positive for antigen .• versus 51% of cells not stimulated with PorB. Figures are 
representative flow cytometry plots showing gating analysis. Data are 
summarized in Fig. 9. 
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At 4 and 6 hours in WT C57BU6 cells, the addition of PorB to Ova in the 
media increased the fraction of Ova-A594 positive DCs above the background 
uptake of cells given Ova alone (Fig. 9). Neither LPS nor Pam3CS~ had this 
effect. After 24 hours of stimulation, both PorB and LPS increased the fraction of 
DCs that took up Ova from the media. The parity between TLR ligands at 24 
hours is similar to that observed for BMDMs, although it should be noted that at 
no time point did Pam3CS~ increase the fraction of antigen-positive BMDCs. 
This may be due to a previously observed effect specific to murine BMDCs in 
which stimulation with the soluble TLR2 ligand Pam3CSK4 did not increase 
antigen processing and presentation, while stimulation with a particulate TLR2 
ligand derived from Mycobacterium bovis did [148]. The addition of PorB also 
took longer to take effect in BMDCs, with no effect observed until 4 hours of 
treatment, in contrast with BMDMs where an effect was observable within 2 
hours of treatment. As responses to TLR stimulation in DCs were delayed in 
BMDCs as compared to BMDMs, as seen in the response to PorB, 24 hours may 
also not have been enough time to observe the effect of Pam3CS~ on antigen 
uptake in BMDCs. 
76 
70 . 
(/) 
0 60 c . 
+ s::: 
Q) 
C') 
:;::::; 50 
s::: 
< 
~ 0 
40 llrl 
* 
* 
~ 
~ 
Time (h) 
~ 
~ E 
~ ~ 
E ~ 
Ill Ova 
§3 Ova+ PorB 
e Ova + Pam3CSK4 
IIID Ova + LP S 
Figure 9: PorB increases antigen uptake in dendritic cells. BMDCs 
were stimulated with Ova-A594 and TLR ligands; antigen uptake was measured 
by flow cytometry. Antigen uptake was measured as the percentage of CD11c 
positive cells that had a signal in the Alexa-594 channel above background. At 4 
and 6 hours after stimulation a significantly higher percentage of BMDCs took up 
Ova-A594 when in the presence of PorB as compared to co-stimulation with LPS 
or Pam3CSK4, or when given Ova alone. After 24 hours of stimulation BMDCs 
stimulated with PorB or LPS had similar fractions of Ova-A594 positive cells, both 
higher than cells stimulated with Pam3CS~ or Ova alone. *: p<0.05, n=3, data 
represents one of three independent experiments. 
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PorB drives increased antigen uptake in DCs in a TLR2 dependent, MyD88 
independent manner 
With the confirmation that stimulus with PorB increased antigen uptake in 
DCs similar to how it affected macrophages, I next repeated the DC antigen 
uptake experiments using cells derived from TLR2 KO and MyD88 KO mice. As 
with the antigen uptake experiments on macrophages, using the knockout cell 
lines would confirm that the observed effect of increased antigen uptake was 
dependent on the known TLR2 binding activity of PorB. The results of the 
experiments using DCs derived from knockout mice were in line with those 
observed in macrophage cells. Cells derived from TLR2 KO mice did not 
increase their uptake of antigen in response to stimulus with PorB in comparison 
to cells stimulated with Ova alone at any time point, and at 24 a higher fraction of 
cells took up antigen after stimulus with LPS (Fig. 1 0). This confirms that 
increased antigen uptake in response to stimulation with PorB is a TLR2 
dependent process. Dendritic cells derived from MyD88 KO mice and stimulated 
with PorB did take up more antigen than cells given Ova alone at 4, 6, and 24 as, 
comparable to the results obtained from DCs derived from WT mice (Fig. 1 0). At 
24 hours, dendritic cells derived from MyD88 KO mice and stimulated with LPS 
took up more antigen than cells given Ova alone. These re-sults confirm the TLR2 
dependence, and the MyD88 independence, of the increase in antigen uptake 
observed in macrophages is recapitulated in DCs. 
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Figure 10: PorB drives antigen uptake in DCs in a TLR2 dependent and 
MyD88 independent manner. Dendritic cells derived from TLR2 KO or My088 
KO mice were stimulated in vitro with Ova-Aiexa594 with or without PorB, 
Pam3CS~ or LPS for 2, 4, 6 or 24 hours. A) Cells derived from TLR2 KO mice 
show no increase in antigen uptake in response to stimulation with PorB at any 
time point. At 24 hours stimulation with LPS is sufficient to increase antigen 
uptake as compared to cells given Ova alone. B) Cells derived from MyD88 KO 
mice show increased antigen uptake in response to stimulation with PorB at 4, 6, 
and 24 hours, and increased antigen uptake in response to stimulation with LPS 
at 24 hours. *: p<0.05, n=6, data represents one of two experiments. 
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Increased antigen uptake in response to PorB is visible under fluorescent 
microscopy 
I next determined if the effects of PorB on antigen uptake observed by 
flow cytometry could be confirmed by fluorescent microscopy. The six hour time 
point was chosen, as this was when the largest effects of PorB on antigen uptake 
were observed in the flow cytometry studies. Widefield image comparisons 
demonstrate that qualitatively more antigen was taken up by cells co-stimulated 
with PorB as compared to cells given Ova alone, or along with LPS (Fig. 11). 
These results agree well with those obtained by flow cytometry. The effect of 
PorB on antigen uptake may appear greater in imaging studies than it does using 
flow cytometric analysis due to the greater dynamic range of the flow cytometer. 
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Figure 11: 40x fluorescent micrographs of WT BMDMs stimulated for 
6 hours with Ova-A594 with or without TLR ligands. A) Alexa594-labeled 
Ovalbumin (10 j.Jg/ml) B) Ova+ LPS (100ng/ml) C) Ova+ PorB (10 j.Jg/ml). All 
images captured with a 14ms exposure; cells stimulated with PorB fluoresce 
brighter. Cells counterstained with DAPI. (Insets): Maximum intensity projections 
of the A594 channel made using deconvolution of z-stacks of regions of interest 
of A-C. There may be a change in the intra-cellular distribution of fluorescent 
antigen, with diffuse staining throughout the cytoplasm cells stimulated with Ova 
alone or in combination with LPS, and a more punctate distribution in the 
presence of PorB. Images representative of fields from three separate 
experiments. 
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In determining the subcellular distribution of Ova under each stimulation 
condition, it can be observed that in cells given Ova alone or in conjunction with 
LPS, the Ova appears diffusely distributed throughout the cytoplasm. In contrast, 
in cells co-stimulated with PorB, the Ova appears collected into punctate 
structures. It is possible that these represent endosomal structures, presumably 
phagolysosomes. 
PorB drives increased cellular recruitment to secondary lymphoid tissue 
when used as a vaccine adjuvant 
We were interested in determining if the adjuvant activity of PorB could be 
explained in part by increased recruitment of APCs to secondary lymphoid 
organs. Delivery and presentation of antigen in lymph nodes plays an essential 
role in the development of adaptive immunity and thus represents a possible 
pathway through which PorB may mediate a portion of its adjuvanticity. I chose a 
hock vaccination model to allow for each mouse to serve as its own internal 
control. In this model APCs from the vaccinated hock migrate to the draining 
popliteal lymph on the same leg that received the vaccine but do not cross the 
midline to the contralateral lymph node. This was confirmed by the absence of 
any antigen-positive cells in mice given labeled antigen in one leg only (data not 
shown). 
Popliteal lymph nodes draining hocks vaccinated with Ova + PorB 
contained significantly (p<0.02) more cells 24 hours after vaccination than those 
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draining hocks vaccinated with Ova alone (Fig. 12). Draining lymph nodes from 
hocks vaccinated with Ova alone, in turn, contained more cells than lymph nodes 
draining hocks mock vaccinated with PBS. Vaccination of the contralateral leg 
with Ova + PorB versus PBS had no effect on the number of cells in lymph node 
draining a site vaccinated with Ova alone. Based on the absence of contralateral 
increases in lymph node cell count it is demonstrated that the effect of PorB on 
increased migration is local, rather than systemic. 
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Figure 12: Cell counts from the draining popliteal lymph nodes of 
mice given hock vaccinations of Ova with or without PorB. Draining popliteal 
lymph nodes were collect 24 hpi. Draining lymph nodes of hocks that had 
received PorB in addition to Ova had significantly higher numbers of cells than 
those receiving Ova alone or PBS. There was no increase in cellularity after 
receiving PorB in the contralateral hock. *p<0.02, n=8 data represents one of 
two experiments. 
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Vaccination with PorB as an adjuvant increase the fraction of DCs in the 
draining lymph node that contain antigen 
I next hypothesized that the inclusion of PorB into the vaccine formulation 
would have the same effect on APCs in vivo as it did in vitro. I chose to examine 
dendritic cells for this study as they play a critical role in antigen presentation 
within the lymph node. In lymph nodes draining hocks vaccinated with Ova+ 
PorB, a higher percentage of dendritic cells were found to be antigen positive, as 
determined by the presence of an Ova-A594 signal above background, when 
compared to lymph nodes draining hocks that had been vaccinated with Ova 
alone (Fig. 13). Mock vaccination with PBS resulted in no antigen-bearing 
dendritic cells even when the contralateral leg was vaccinated with Ova, 
confirming an absence of midline crossover and the validity of the internal 
controls (data not shown). 
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Figure 13: Vaccination with PorB as an adjuvant increase the fraction 
of antigen-positive dendritic cells in the draining lymph node. C57BL/6J 
mice were given vaccine injections in the left and right rear hock: 10 IJg Ova-
A594 to the left hock, 10 !Jg Ova-A594 + 10 !Jg PorB to the right hock. 24 hours 
post injection, mice were sacrificed and single cells suspensions from the 
draining lymph nodes were stained for CD11 band CD11 c and examined using 
flow cytometry. CD11 b/CD11c positive DCs were gated, and the proportion of 
A594+ cells quantified . Lymph nodes draining sites that had received adjuvanted 
vaccines had a significantly higher percentage of DCs carrying antigen . *: 
p<0.005 n=4, data represents one of two experiments. 
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A greater number and wider distribution of antigen bearing cells are visible 
in lymph nodes after vaccination with PorB as an adjuvant 
For a more detailed investigation of APC and antigen trafficking to draining 
lymph nodes following vaccination I made fresh frozen sections of popliteal 
lymph nodes following hock vaccination and examined them under widefield 
fluorescent microscopy. 8 !Jm sections were made and acetone fixation was used 
to preserve tissue structures. Sections from a lymph node draining a hock 
vaccinated with Ova alone revealed sparse antigen positive cells around the 
periphery of the lymph node (Fig. 14). In contrast, lymph nodes draining hocks 
vaccinated with Ova + PorB had more antigen positive cells, and those cells 
penetrated into the interior of the lymph node. Control lymph nodes draining 
hocks mock vaccinated with PBS showed no antigen present (not shown). 
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Figure 14: Fluorescent micrographs of 8 1Jm fresh frozen sections of 
popliteal lymph nodes of mice, 24 hours post vaccination in the hock. Ova-
A594 fluoresces red, sections were counterstained with DAPI in blue. A) Section 
of a node draining an ankle vaccinated with 10 IJg Ova-A594. A few peripheral 
cells are antigen positive. B) Section a node draining an ankle vaccinated with 
1 0 1-1g Ova-A594 plus 1 0 1-Jg PorB as an adjuvant. Antigen positive cells are 
present in greater numbers and have penetrated into the interior of the lymph 
node. Micrographs are representative images of 8 nodes examined for each 
vaccination condition. 
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Ch. 2 Conclusions 
In summary, I demonstrate here that stimulation with PorB acts to 
increase antigen uptake and migration by cells of the innate immune system. 
While these processes are known to be important during the immune response, 
and have been studied with regards to other TLR ligands, the effects of PorB on 
these functions of the innate immune system has previously not been known. I 
examined the effect of stimulation with PorB on antigen uptake in macrophages 
and dendritic cells, and found that antigen was taken up more rapidly when the 
cells were stimulated with PorB, as compared to stimulation with other TLR 
ligands, or in response to antigen alone. Based on previous work in the lab 
showing the dependence of PorB immune stimulating functions on TLR2 and 
My088, I repeated the antigen uptake experiments in cells that lacked either 
gene, and found that TLR2 was essential for the increase in antigen uptake 
observed in response to PorB stimulation, while MyD88 was not. This was not 
expected, as MyD88 has been shown to be essential in all previous effects of 
PorB our lab has studied. This suggests that PorB interacts with the antigen 
uptake pathway through a MyD88 independent pathway; such a pathway could 
make for a future study of interest. The demonstration that both antigen uptake 
and APC migration can be modulated simultaneously by PorB suggests that 
these are viable targets for further refinement in vaccine design and should be 
considered in the development of next-generation vaccine adjuvants. 
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Chapter 3: Transcriptome analysis of mouse splenocytes when PorB is 
used as a vaccine adjuvant in a multi-injection vaccine schedule 
Microarray experiments have the ability to survey the complete expression 
profile a tissue or cell sample [96]. Combined with advances in systems biology 
analysis techniques, it has become possible to characterize the entire response 
of a system to stimulus to a depth previously unobtainable. I was interested in 
using these techniques to study the response of the immune system to 
vaccination when using PorB as an adjuvant. The purpose-was to confirm 
previous observations of immune pathways activated by PorB and to potentially 
reveal inflammatory networks not previously known to be influenced the inclusion 
of porin. In total, two microarray studies were performed: an initial experiment 
that examined the effect of PorB only after the third of three vaccinations, and a 
follow up experiment that investigated the effect of PorB after each of the three 
vaccinations. 
Microarray analysis of the effects of PorB inclusion in a vaccine 
formulation on expression of genes in splenocytes 
In designing the first microarray experiment, I was interested in 
determining the effects of PorB on the immune system , both alone and in in 
combination with Ova. The same three vaccination schedule was used that we 
have previously demonstrated highlights the adjuvant functionality of PorB [26]. 
Sample collection 24 hours after the third vaccination was chosen as it was 
expected to maximize the potential for innate immune signaling. While PBMCs 
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have been a common choice source for RNA in human microarray studies [149], 
splenocytes were chosen to maximize both the quantity of RNA that could be 
recovered and the range of possible cell types RNA would be recovered from. 
Once the expression values for each gene had been obtained, I was 
interested in determining if there were any significant differences between the 
mice receiving each vaccine formulation . ANOVA analysis of all of the genes 
from the microarray revealed 289 genes significantly regulated at p<0.001 across 
all experimental conditions. This p-value cut-off was chosen in consultation with 
the biostatistician. Although the number of regulated genes was relatively small 
compared to previous studies in the field ofvaccinomics [149, 150], it was 
decided to proceed with further analysis. A clustering analysis was used to 
determine the primary divisions between the vaccine formulations, as well as 
how their patterns of expression in each sample related to each other. Unbiased 
clustering analysis of the 289 regulated genes did group mice from each vaccine 
formulation together. However, the primary division observed was between those 
mice that had received Ova (i.e. the Ova alone and Ova+ PorB formulations) 
and those mice that did not receive Ova (the PBS and PorB alone formulations) . 
This result, implying that the most significant factor in the splenic response was 
the presence of Ova, rather than PorB, was unexpected. To pursue the original 
goal of determining the effects of PorB inclusion, a second analysis was 
performed specifically contrasting mice that did or did not receive PorB as a 
component in the vaccine formulation. 56 significantly regulated genes at 
92 
p<0.001 (Fig. 15) were identified for which expression differed between mice that 
did receive PorB and those that did not. This is a very small number of genes, 
especially given the magnitude of the difference in antigen-specific antibody titers 
known to result from the inclusion of PorB as a vaccine adjuvant. Given such a 
surprising result, I hypothesized that the major regulatory activity of PorB on 
splenocytes may have occurred at a time point other than after the third 
vaccination, and that a new experiment would be required to determine when 
these regulatory effects occurred. 
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Figure 15: Gene regulation after the third of three vaccine injections. Mice 
were vaccinated with 10 IJg Ova, 10 IJg PorB, or 10 !Jg Ova + 10 !Jg PorB. 
Control mice were mock vaccinated with PBS. Significantly regulated genes were 
defined as those for which expression differed between the two groups receiving 
PorB and the two groups that did now. Genes were clustered by pattern of 
expression, and fold change represented as relative to the average of PBS 
controls. n=3, experiment performed once. 
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Microarray analysis after each of three vaccine injections 
Based on the results of the first microarray experiment, I hypothesized that 
the critical regulatory steps that occur when PorB is used as a vaccine adjuvant 
may be occurring some time before the third vaccine injection. To determine if 
this was the case, a second microarray experiment was designed to investigate 
the splenic response after each of three vaccinations. The vaccination schedule 
and the choice of the spleen as the source of RNA were kept the same for the 
reasons outlined above. 
Statistical analysis of the microarray data began with a principle 
component analysis (PCA). PCA is used to identify major subpopulations within 
the samples within which gene expression is significantly different from all other 
samples. The two principle components PC 1 and PC2 accounted from 25% and 
14% of all inter-sample variability respectively in gene expression. Clustering of 
samples from one or more conditions would have indicated major systematic 
changes in gene expression between individual samples. As all of the samples 
were obtained from the same source tissue (spleen) no such clustering was 
expected. PCA revealed no clustering of samples or significant outliers due to 
technical effects (Fig. 16). 
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Figure 16: Principle component analysis of all microarray samples. 
PCA was applied to all 30 samples of the second microarray data set. Clustering 
was not observed in either of the two principle components. 
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Our initial analysis of the microarray data was concerned with the kinetics 
of the response within each vaccine formulation . I knew from the earlier 
microarray experiment that by the third injection there were relatively few genes 
that varied between mice that did and did not receive PorB as an adjuvant in their 
vaccinations. To determine if PorB had an effect earlier in the schedule of the 
vaccination than the third injection, two models of gene regulation over time were 
constructed. The first was a linear or "monotonic" model. This model selected 
genes that varied in a continuous direction over the course of the vaccination 
schedule. Specifically, Day 0 was given an ordinal value of 0, Day 14 an ordinal 
value of 1, and Day 28 an ordinal value of 2. Genes were then scored according 
to how their expression across all three time points within a single vaccination 
conditions correlated with the model. That is, either a significantly regulated 
gene's expression might start at one point after the first injection, increase after 
the second , and increase still further after the third. Alternately, it could decrease 
after the second and still further after the third. The former scenario was reported 
as a positive t value with a high absolute magnitude, while the latter was reported 
as a negative t value with a similarly large absolute magnitude. This model 
represented what could be considered a classic model of vaccine response, with 
each successive vaccination generating a larger and larger response. 
In mice vaccinated with Ova alone, 927 genes were determined to be 
significantly regulated (p>0.005) in a monotonic fashion. (Fig. 17) The higher p-
value cut-off of p<0.005 was chosen in consultation with Adam Gower, due to the 
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more stringent filtering done before statistical analysis and the increased power 
of the Bayesian model used. Many of the upregulated genes, those for which 
expression increased over the course of the vaccination schedule, were those 
involved in cell cycle control and regulation. This category included a number of 
proto-oncogenes including Brca1 and Brca2, as well as cyclin and Cdk genes. 
Elements of the ATPase associated with its function in lysosomes were also 
observed to be upregulated, which may be related to increased processing of 
antigen for presentation. Genes downregulated in mice vaccinated with Ova 
alone included a wide range ofT cell associated genes, including CD3, CD4, 
CD8 and the transcription factors Foxo1 and GATA3. 
In mice vaccinated with Ova + PorB, only 77 genes were determined to be 
regulated (p<0.005) in a monotonic fashion (Fig. 17). Only six of these genes 
overlapped with those monotonically regulated in mice vac_cinated with Ova 
alone. No significant patterns within the regulated genes were observed. 
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Figure 17: Regulated genes under a monotonic model. Gene 
expression from mice vaccinated with Ova alone or Ova + PorB were fit to a 
monotonic model of regulation following each of three injections (p<0.005). 
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The second model constructed was a V-shaped or "revertant" model. In 
developing this model, it was hypothesized that the major regulatory events 
initiated by PorB as an adjuvant occurred by the second vaccination. After the 
third vaccination, then, it would be expected that many of those genes would only 
be expressed at a level equivalent to the first vaccination. Such a pattern of 
expression would explain why in the first microarray experiment relatively few 
genes were seen that showed differential regulation after a third injection with the 
inclusion of PorB in the vaccine formulation: with the key regulatory steps 
completed, expression of those genes could have returned to a level 
commensurate with a vaccination that did not include the adjuvant. To model this 
predicted behavior gene expression levels at Days 0 and 28 were grouped 
together, and compared to day 14. Genes were designated as regulated in a 
revertant manner if their expression at Day 14 was significantly different that at 
Day 0 and Day 28 within a single vaccine formulation. A positive t value 
represented expression that increased at Day 14 and then declined, while a 
negative T value indicated expression decreased at Day 14 and then recovered. 
In mice vaccinated with Ova alone, 69 genes were determined to be 
significantly regulated (p<0.005) in a revertant fashion. No significant patterns to 
the genes were observed. In mice vaccinated with Ova+ PorB 384 genes were 
determined to be regulated (p<0.005) in a revertant fashio~ (Fig. 18). 
Upregulated genes, i.e. those for which expression peaked at day 14, included 
lysosome-affiliated elements of the ATPase proton pump, as seen in 
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monotonically regulated genes for mice vaccinated with Ova alone. Expression of 
multiple components of immunoglobulins, including heavy, light and constant 
regions, also peaked at Day 14. Downregulated genes included Calmodulin and 
components of the extracellular matrix. There were no genes regulated in a 
revertant manner in both mice vaccinated with Ova alone and mice vaccinated 
with Ova + PorB (Figure 19). 
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Figure 18: Genes regulated in a revertant manner in mice vaccinated with 
Ova + PorB. Mice were vaccinated with 10 j..lg of Ova + 10 j..lg of PorB and given 
1, 2 or 3 injections 2 weeks apart. A) Regulated genes were defined as those 
which fit a model in which expression on Day 14 was significantly higher (red) or 
lower (blue) on Day 14 than on Days 0 and 28. Columns are individual mice. B) 
Gene Set Enrichment Analysis output for 4 genes sets determined to be 
positively enriched under the revertant model in mice vaccinated with Ova + 
PorB. Gene sets are representative of the inflammatory, immune signaling, and 
lysosomal pathways generally determined to be enriched in a revertant manner 
when PorB is included as a vaccine adjuvant. 
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Figure 19: Regulated genes under a revertant model. Gene expression 
from mice vaccinated with Ova alone or Ova + PorB were fit to a revertant model 
of regulation following each of three injections (p<0.005). There were no genes 
overlapping between the two formulations 
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Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) was chosen to interpret the large 
number of diverse genes returned as significant over the multiple comparisons. 
Additionally, the initial statistical analysis returned a large number of genes 
expected to be in related ontology categories at slightly under statistical 
significance. Using enrichment analysis of the entire genome made it possible to 
aggregate these genes to uncover statistically significant conclusions. GSEA 
analysis was performed for the each time course models for the Ova alone and 
Ova + PorB vaccine formulations, as well as pairwise comparisons between the 
two formulations at each time point. For each of the time course models, 
enrichment was determined as positive or negative: positively enriched or 
upregulated sets were those for which the genes in the set clustered with large 
positive t statistics, while the inverse held for negatively enriched sets. This was 
interpreted as general up or down regulation respectively of the pathway 
represented by those genes within the model. For the pairwise comparisons, t 
statistics represented the over or under expression of the gene in mice 
vaccinated with Ova + PorB relative to mice vaccinated with Ova alone. "Positive" 
enrichment thus indicated that the genes in the set were expressed higher at that 
time point in mice vaccinated with Ova + PorB relative to Ova alone. 
Using the monotonic model there were 264 positively upregulated genes 
sets in mice vaccinated with Ova alone as defined by an FDRq<0.25. Many of 
these gene sets, including every member of the top twenty most enriched sets, 
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were related to the cell cycle and proliferative processes. In total at least 87 gene 
sets dealt with replication and associated processes, while only 3 were involved 
in inflammation or responses to pathogens. Additionally there were 392 
negatively regulated genes sets in mice vaccinated with Ova alone. Negatively 
regulated sets included T cell processes, TLR signaling cascades, chemokines 
and innate immunity, and the MAPK and NF-KB signaling pathways. In contrast, 
there were no enriched gene sets in either direction under the monotonic model 
in mice vaccinated with Ova + PorB. 
Using the revertant model there were 244 positively regulated (peaking at 
Day 14) genes sets in mice vaccinated with Ova+ PorB at an FDRq<0.25. These 
sets covered TLR signaling, endocytosis and lysosomal digestion, cell 
proliferation, and signaling through multiple cytokines. Inflammatory signaling 
cascades predominated , including nine of the top twenty pathways (Fig. 18b). In 
addition to generalized inflammatory pathways, GSEA analysis also revealed 
similarities to signaling pathways for other receptors that have been targeted by 
experimental adjuvants. These included upregulation of genes seen in TLR3, 
TLR9, and RIG-I mediated inflammatory responses. At least 56 of these gene 
sets were related to immunity and inflammatory processes, with another 13 
specific for proliferation. Additionally there were 132 genes sets negatively 
regulated under the revertant model in mice vaccinated with Ova+ PorB. 
Downregulated gene sets included those for ion channels, cell adhesion and the 
ECM. Heatmap analysis of the Toll Receptor Cascade gene set positively 
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regulated under the revertant model in mice vaccinated with Ova + PorB shows a 
majority of the genes comprising the pathway peaking at Day 14, after the 
second injection (Fig. 20). This can also be seen in the GSEA output, 
demonstrating that the majority of the genes within the set have high positive t 
values under the revertant model. 
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Figure 20: Detailed analysis of a single gene set positively enriched in the 
revertant model of mice vaccinated with Ova + PorB. A) GSEA analysis of 
Reactome Toll Receptor Cascade gene set using a ranked analysis of the 
revertant model for mice vaccinated with Ova + PorB. The set is enriched for 
genes positively regulated after vaccination with Ova + PorB. This includes 
genes individually significantly regulated (p<0.005) as well as a number of genes 
just below the threshold for individual significance (0.005<p<0.01). B) Heat map 
of all of the genes in the Reactome Toll Receptor Cascade gene set. Gene 
expression was normalized across all mice vaccinated with Ova + PorB and fold 
changes calculated for each mouse. Genes were sorted by moderated t value 
using the revertant model. 
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I next determined the extent of the overlap between the Ova monotonic 
model and the Ova + PorB revertant model. Extensive similarities between the 
two would imply that the inclusion of PorB as an adjuvant resulted in an 
acceleration of the same regulatory events that would occur in mice vaccinated 
with Ova alone without activating any additional pathways. Only four genes were 
found to be significantly (p<0.005) regulated in both a monotonic fashion in mice 
vaccinated with Ova alone and in a revertant fashion in mice vaccinated with Ova 
+ PorB. This is well within the probability of random chance, and suggests that 
there is no significant overlap between individual genes. However, as was shown 
in the initial gene set analysis, there exist a large number of gene sets enriched 
for up regulated genes under each of those conditions, even if few individual 
genes reached statistical significance. We therefore determined if there was 
significant overlap in the enriched gene sets overlap between the Ova monotonic 
and the Ova + PorB revertant models. 23 gene sets were positively enriched in 
both models. These gene sets included multiple members relating to the cell 
cycle, replication, and associated processes like DNA repair. This correlates with 
the initial analysis of gene sets from each model, wherein the revertant model of 
the mice vaccinated with Ova + PorB had all the cell cycle and proliferation gene 
sets of the mice vaccinated with Ova alone, but also were significantly enriched 
in inflammatory processes not observed in the monotonic model of mice 
vaccinated with Ova alone. 
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A detailed comparison was made between one gene set in the top 20 
most highly enriched sets of both the Ova alone monotonic model and the Ova+ 
PorB revertant model (Fig. 21) . This was done to better understand the 
differences in the kinetics of the responses to each vaccine using a more easily 
manageable set of data. For this analysis the G2-M Checkpoint gene set from 
Reactome was used. From the GSEA data it is evident that the genes in the set 
are highly and uniformly regulated in a monotonic manner across the vaccination 
schedule in mice vaccinated with Ova alone. In contrast in mice vaccinated with 
Ova + PorB while the genes cluster towards positive correlation and fitting of the 
revertant model, it is not to the same extent as observed in their Ova monotonic 
counterparts. To examine this further a heatmap was made of the expression of 
all of the genes in the G2-M Checkpoint set and their expression in each of the 
mice across all of the time points for both the vaccine formulations. The average 
expression level for each gene across all of the samples was determined, and 
the fold expression of that gene in each of the samples relative to the average 
was plotted. In this analysis it is evident that in the mice vaccinated with Ova 
alone significant upregulation only occurs following the third vaccination. When 
the data for the mice vaccinated with Ova + PorB was examined, it was observed 
that the genes within the set were generally upregulated following the second 
vaccination, as predicted by the revertant model. However, one mouse 
demonstrated upregulation after only one vaccination, while another still showed 
increased expression after the third vaccination. While vaccination with PorB thus 
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does appear to increase the rapidity with which these genes were upregulated , it 
may also be introducing an element of variability to the response. It is this 
variability that may explain the lower t statistics for individual genes in mice 
vaccinated with Ova+ PorB even while the gene set as a whole remained 
significantly enriched. 
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Figure 21: Comparison of gene expression between mice vaccinated with 
Ova alone and Ova + PorB. One gene set was selected that was positively 
enriched in both mice vaccinated with Ova alone under the monotonic model and 
mice vaccinated with Ova + PorB under the revertant model. A) GSEA output for 
the Reactome G2-M Checkpoint gene sets using ranked gene lists from both 
models. Genes cluster as highly significant under the Ova monotonic model, 
while they are less significant under the Ova + PorB revertant model. B) 
Heatmap generated from all the genes within the Reactome G2-M Checkpoint 
gene set for all of the mice vaccinated with each of the vaccine formulations 
sorted by moderated t value. It can be observed that clear partitioning is evident 
in the mice vaccinated with Ova alone. Mice vaccinated with Ova + PorB tend to 
show highest expression of these genes after the second vaccination although 
outliers are present. 
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The above results indicate a significant difference in the kinetics of the 
response to vaccines adjuvanted with PorB as compared to vaccines comprised 
of only the antigen. Two competing hypotheses could account for this difference. 
The first is that PorB does actually accelerate the observed response, resulting in 
larger and/or more rapid changes in gene expression in the mice that receive it. 
In contrast, PorB could be truncating the responses observed when mice were 
vaccinated with Ova alone, resulting in an earlier downturn in expression (Fig. 
22a). To determine which of these hypotheses were correct, the rate of change 
of expression observed for each vaccine formulation was calculated. 
To calculate the rate of change of gene expression following vaccination 
with each formulation those genes from mice vaccinated with Ova alone that fit 
the monotonic regulation mode were selected, as well as those genes from mice 
vaccinated with Ova + PorB that fit the revertant model. For genes from the Ova 
+ PorB revertant model, the fold change in expression for each gene between the 
first and second vaccinations was calculated. As this change occurred over the 
two-week time period between vaccinations, the calculated value was the rate of 
change of expression per "interval" of time. The absolute value of fold induction 
was used to generate a one-tailed histogram. For genes from the Ova monotonic 
model, the fold change in expression between the first and third vaccinations was 
calculated. As this change in expression occurred over four weeks of time, rather 
than two, the change in fold expression were then halved to obtain the rate of 
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change over the same interval as the genes from the Ova+ PorB model (Fig. 
22b). 
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Figure 22: Rate of induction of genes after vaccination with Ova vs 
Ova+ PorB. A) Model describing the two hypotheses tested. Ova+ PorB 
Revertant represents gene expression in mice vaccinated with Ova + PorB over 
the course of three vaccinations for those genes expressed in a revertant 
manner. Ova Monotonic High and Ova Monotonic low represent two possible 
patterns of gene expression in mice vaccinated with Ova alone. In Ova 
Monotonic Low, mice vaccinated with Ova alone achieve the same fold gene 
induction after three vaccinations that mice vaccinated with Ova + PorB achieve 
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Monotonic Low, mice vaccinated with Ova alone achieve the same fold gene 
induction after three vaccinations that mice vaccinated with Ova+ PorB achieve 
after two vaccinations. In Ova Monotonic High, mice vaccinated with Ova alone 
have comparable gene expression levels to mice vaccinated with Ova + PorB 
after two vaccinations, but continue to increase gene expression after the third 
vaccination. Differentiation between the two models is possible by determining 
the slope of each line, i.e. the rate of change of gene expression. B) The rate of 
fold induction for each gene regulated in a monotonic manner in mice vaccinated 
with Ova alone and each gene regulated in a revertant manner in mice 
vaccinated with Ova+ PorB was calculated. Genes were plotted in a histogram 
with relative frequency on the y-axis to account for an unequal number of genes 
in each set. Mice vaccinated with Ova+ PorB showed significantly higher rates of 
induction in gene expression as compared to mice vaccinated with Ova alone.*: 
p<0.0001. 
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Mice vaccinated with Ova + PorB had a higher median rate of change in 
gene expression than mice vaccinated with Ova alone, as measured by a non-
parametric Mann-Whitney test (p<0.0001). This can be observed as the 
histogram of revertant Ova + PorB genes peaks to the right of the monotonic Ova 
alone genes (Fig 22b). The higher rate of induction when PorB is included in 
vaccine formulation confirms the hypothesis that PorB accelerates the kinetics of 
the vaccine response. 
Pairwise comparisons between Ova and Ova + PorB formulations 
In addition to studying the effects of PorB on the kinetics of the vaccine 
response, I was also interested in investigating specific pathways activated when 
PorB is present in a vaccine injection. To directly compare the effects of the 
inclusion of PorB as an adjuvant in the vaccine formulation at each time point 
pairwise comparisons were performed. At each time point, the expression of 
each gene was contrasted between mice that received Ova alone and mice that 
had received Ova plus PorB. A the suggestion of biostatistician Adam Gower this 
analysis was performed for just the genes in the top quartile by variance across 
all samples to increase statistical power. 
24 hours after the first vaccine injection, 57 genes were expressed at 
significantly higher (p<0.01) levels in mice that had been Ova+ PorB when 
compared to mice vaccinated with Ova alone. GSEA analysis using the 
moderated t statistics from this comparison revealed an additional 192 gene sets 
(FDRq<0.25) that were significantly enriched in genes upregulated in the mice 
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that had received Ova+ PorB (Table 1). These gene sets were predominately 
involved in cell cycle and proliferation. To determine the cause of the relatively 
large number of positively enriched gene sets given the small number of 
significantly regulated genes, the GSEA output was more closely examined. In 
many case the plurality of the genes within the set trended towards higher 
expression in the mice that had received the adjuvanted vaccine but individually 
did not reach the threshold for statistical significance. However, once taken in 
aggregate it appeared clear that these pathways were being enriched due to the 
addition of the adjuvant. 
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Table 1: Summary of regulated genes and gene sets using pairwise 
comparisons. Pairwise comparisons were made between mice vaccinated with 
Ova alone and Ova + PorB after 1, 2 and 3 injections with each vaccine 
formulation. Significantly regulated genes were defined as those for which the 
difference in expression between mice vaccinated with the two formulations had 
a p<0.01. Ranked lists using the moderated t values from the pairwise 
comparisons at each time point were used in Gene Set Enrichment Analysis. 
Day 1 Day 15 
p<0.01 p<0.005 FDRq<0.25 p<0.01 p<0.005 FDRq<0.25 
Ova 108 59 345 257 108 187 
O+P 57 30 192 415 267 375 
Day 29 
p<0.01 p<O.OOS FDRq<0.25 
Ova 29 15 198 
O+P 53 28 107 
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After a single vaccination 108 genes were expressed at significantly lower 
levels in mice that had been vaccinated with Ova + PorB when compared to mice 
vaccinated with Ova alone. Using the same GSEA analysis as above, an 
additional 349 gene sets were determined to show enrichment in comparatively 
downregulated genes (Table 1 ). These gene sets included representatives of 
inflammatory processes, innate and adaptive immunity, and intra- and extra-
cellular signaling. 
By Day 14 and the second injection, the number of genes upregulated in 
mice that had received Ova + PorB relative to mice that had received Ova alone 
increased to 415, and the number positively enriched gene sets to 375 (Table 1). 
Specific genes more highly expressed in mice vaccinated with Ova + PorB 
include multiple components of the immunoglobulins and T cell receptors. Cell 
cycle related genes such as Brca1 and Brca2, as well as Cyclin E1, E2 and F 
and Cyclin dependent kinase (Cdk) 1 were also more highly expressed. Enriched 
gene sets include the same cell cycle and proliferation pathways observed after 
the first vaccination, but now also included gene sets involved in lysosomal 
degradation of proteins. A number of gene sets involved in T cell signaling 
through the T cell receptor (TCR) as well as CD28 and CTLA4 were also 
enriched in upregulated genes. This agrees well with previous research that has 
shown that PorB is able to convert T -independent adaptive immune responses to 
T -dependent responses. 257 genes were found to be expressed at lower levels 
after inclusion of PorB into the vaccine formulation, along with 187 gene sets. 
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These gene sets included elements of ion channel pathways, cell-cell adhesion, 
and cell-cell signaling. Interestingly IFN-a was observed to be downregulated 
with the inclusion of PorB in to the vaccine formulation. 
Results after the 3rd and final injection mirrored thos·e of the earlier 
microarray study. Only 53 genes were upregulated in mice vaccinated with Ova+ 
PorB, as compared with mice vaccinated with Ova alone (Table 1). A total of 107 
gene sets, however, could be identified as being enriched for positively regulated 
genes in the mice receiving Ova + PorB. These gene sets included innate and 
adaptive pathways, as well as MyD88 regulated events and gene sets identified 
as reactions to pathogens. At Day 28 only 29 genes were expressed at lower 
levels when mice received PorB in addition to Ova in their vaccine formulation. 
Differential gene regulation and enrichment in gene sets at each time point are 
summarized in Figure 23. 
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Figure 23: Comparison of relative expression between mice vaccinated 
with Ova and Ova + PorB after each of three vaccinations. Variations in 
individual gene expression (solid bars, left axis) due to the inclusion of PorB were 
highest after the second vaccination. GSEA (hashed bars, right axis) 
demonstrates a larger effect on the relative expression of gene sets due to the 
inclusion of PorB in the vaccine formulation after the first and second injections, 
decreasing by the third injection. As each gene may be included in multiple gene 
sets, and a gene set may be considered significantly regulated even if many of 
the genes comprising it are not individually significantly regulated, it is possible to 
have more genes sets regulated than individual genes. 
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The results after the final vaccination do not suggest that tlie third vaccination 
had no effect on the mouse at all. Mice vaccinated with either Ova alone or Ova 
+ PorB each had over 500 genes differentially regulated to mock vaccinated mice 
after the third vaccination. Rather, then, by this point the two vaccinations appear 
to have developed similar patterns of expression (Fig. 23), while still maintaining 
significant effects relative to mock vaccinated mice. 
We knew from the above analysis that expression of a number of gene 
sets peaked at Day 14 for mice given Ova+ PorB, while mice given Ova alone 
expressed many gene sets highest at Day 28. I hypothesized this shift in 
expression within each vaccine formulation would be apparent when comparing 
formulation with each other. To make this comparison I looked for gene sets that 
were expressed higher at Day 14 in mice vaccinated with Ova+ PorB when 
compared to Ova, and higher in mice vaccinated with Ova alone at Day 28. 
Remarkably, 148 gene sets matched these criteria, out of 375 expressed higher 
in Ova+ PorB mice at Day 14 and 198 expressed higher in Ova alone at Day 28 
(Fig. 24). These overlapping gene sets were overwhelmingly composed of those 
representing cell cycle and proliferation pathways. 
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Figure 24: Overlap between gene sets elevated after administration of a 
given vaccine formulation after each vaccination. Comparisons were made 
between mice vaccinated with Ova + PorB versus Ova alone at each time point. 
A) Overlap between gene sets positively enriched in mice vaccinated Ova + PorB 
after second the second vaccination and gene sets positively enriched in mice 
vaccinated with Ova alone after the third vaccination. B) Overlap between the 
above gene sets and gene sets enriched after the first vaccination with Ova + 
PorB. 
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Given the significant changes in relative expression between the time 
points I determined which gene sets maintained their expression across multiple 
time points. As has been shown, mice vaccinated with Ova + PorB had some 
similarities after one and two injections as well as with mice vaccinated with Ova 
alone after three injections. Performing an analysis of overlapping gene sets as 
described above revealed 74 gene sets in common between all three groups of 
mice (Fig. 24). These gene sets were predominately related to the cell cycle and 
proliferation. An additional 43 gene sets were found to be in common between 
mice given one and two vaccinations of Ova + PorB but not shared by mice given 
three injections of Ova alone. These gene sets included a number pertaining to 
formation and trafficking of lysosomes and proteasomal digestion. These findings 
agree well with earlier work demonstrating that PorB increases antigen uptake in 
APCs, likely for eventual antigen processing and presentation. While many 
genes showed similar expression after the first two injections of Ova + PorB, this 
changed drastically after the third injection. There were no gene sets enriched for 
upregulated genes after the third vaccination that were also upregulated after 
both the first and second injections of Ova + PorB. 
Comparison of the mice after the third vaccination with Ova + PorB with 
earlier time points reveals that a substantial shift in gene expression occurs at 
the third vaccination. I determined how broad this effect was across the entire 
genome, rather than just those genes for which expression differed from mice 
vaccinated with Ova alone. To do this a new model was generated that grouped 
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expression on Days 0 and 14 together and looked for changes in expression as 
compared to Day 28. Only 67 genes were upregulated at Day 28 (p<0.005) and 
86 were downregulated, suggesting that this model does not describe the major 
trends in vaccination progression. However, 296 gene sets were found to be 
enriched for genes expressed lower after the third injection in mice vaccinated 
with Ova+ PorB than after the first two vaccinations with the same formulation . 
Moreover, these gene sets were richly represented by innate and adaptive 
immune processes. These included the signaling cascades of both the T cell 
receptor and the B cell receptor, as well as TLR signaling. Additional pathways 
including IL-1, IL-7, CD28, and a number of downstream MAPK pathways were 
also represented. There were 103 gene sets enriched for genes expressed at 
higher levels after the third injection. These gene sets were a mix of ion channel 
activity and cell-cell interactions. The inclusion of a number of nerve and olfactory 
pathways in these gene sets suggest they may be noise generated by the large 
number of mouse olfactory genes present in the microarray which were collapsed 
when mapping mouse genes onto human homologs. 
Ch. 3 Conclusions 
My studies of the microarray analysis on the inclusion of PorB as a 
vaccine adjuvant reveal that the major regulatory events driven by PorB occur 
after the second of three injections, and include up regulation of genes and 
pathways responsible for cell division, replication, inflammation, and immune 
signaling . In contrast, mice vaccinated with Ova alone show a pattern of gene 
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regulation whereby gene expression increases steadily over the course of the 
vaccination schedule, with regulation occurring predominantly in genes and 
pathways related to cell division and replication only. As a result of these two 
factors, by the third injection, there are relatively few genes with differential 
expression between mice vaccinated with Ova alone as compared to mice 
vaccinated with Ova plus PorB. These results indicate the existence of a new 
paradigm for gene regulation over the course of multi-injection vaccination 
schedules when an adjuvant in used, and may need to be taken into account 
during the design of novel adjuvants and vaccine formulations. 
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Discussion 
The use of immune adjuvants, other than alum, in human vaccines is 
beginning to be explored [14, 23, 101]. These adjuvants are essential for 
designing vaccines that avoid the potential dangers of attenuated or inactivated 
pathogens, while still eliciting strong protective immune responses. Therefore, 
there is great interest in developing and characterizing new adjuvant candidates 
with novel function and mechanisms of action [151-153]. Research into vaccine 
adjuvants has generally focused on identifying candidate adjuvants and 
measuring their efficacy in model systems [17]. While broad trends have 
emerged in the classes of compounds that are effective adjuvants [96], including 
the TLR ligands [16, 17], less work has been done to determine the specific 
molecular mechanisms by which individual adjuvants can be differentiated from 
one another. To address this issue, one of the aims of our lab's research is to 
elucidate the mechanisms by which one specific TLR ligand, PorB, acts on the 
innate immune system and as a vaccine adjuvant. The unique set of pathways 
affected by each adjuvant is not fully understood, especially for newer adjuvants 
such as PorB [2, 27]. I set out to examine a number of possible pathways 
through which PorB may be stimulating the innate immune system; regulation of 
these pathways would represent possible mechanisms that could explain the 
adjuvanticity of PorB. Additionally, I hypothesized that the activation of these 
pathways occurs via signaling through the known TLR2 agonist activity of PorB. 
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In previous work, we have shown that the N. meningitidis OMP PorB acts 
as an adjuvant in vaccines, increasing the strength of adaptive immune 
responses to a range of antigens including polysaccharides, proteins, and F. 
tularensis LPS [26, 30]. We have also demonstrated that PorB is a ligand of 
TLR2/1 heterodimers [2] and requires My088 for efficient cell signaling [24, 90]. 
Analysis of the TLR2 dependent effects of PorB is therefore essential in linking 
its adjuvant activity to known pathways of innate activation. Such a 
demonstration would establish a clear causal chain, validating the proposed 
mechanism of adjuvanticity. 
Chapter 1: Innate immune activation and adjuvant activity of PorB 
The ultimate goal for any vaccine adjuvant is to elicit a robust antigen-
specific response by the adaptive immune system [154]. As the canonical targets 
of many adjuvants, including PorB, are elements of the innate immune system, 
this requires efficient communication between the innate and adaptive arms. To 
this end, we were interested in the expression of surface proteins on APCs in 
response to PorB. Increased cell-cell communication has been identified as a 
mechanism of adjuvanticity for other adjuvants [51], and plays an essential role in 
the function of live attenuated vaccines that naturally include PAMPs [81, 137]. 
Previous research by our lab had identified MHCII and CD86 as upregulated on 
dendritic cells following stimulus by PorB [90]. As additional targets, proteins 
significant forT cell stimulation (CD40) [136], for APC motility (CD54) [139], and 
markers of BMDM activation (CD14, and CD69) [109] were chosen. Increased 
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surface expression in all of these proteins was observed following stimulation 
with PorB. If APCs stimulated by PorB have the same response in vivo, they 
would be well prepared to activate CD4 and CDS T cells. This would corroborate 
previous work by our lab showing significant increases in the CD4 T cell 
dependent process of class switch recombination driven by the inclusion of PorB 
in vaccine formulations [26], and confirmed by the observation of significantly 
increased antigen-specific lgG in C57BI/6 mice vaccinated with Ova + PorB as 
compared to mice vaccinated with Ova alone. Surprisingly, CD54 and CD69 
expression in TLR2 KO BMDMs stimulated with PorB were still slightly elevated 
when compared to unstimulated cells. Additionally, while TLR2 KO mice 
vaccinated with Ova+ PorB had anti-Ova lgG levels significantly below those of 
WT mice given the same vaccine, they still had higher antibody levels than TLR2 
KO mice vaccinated with Ova alone. While we do not as yet have a confirmed 
mechanism for this weaker adjuvant activity, it does appear to be MyD88-
dependent, as MyD88 KO mice vaccinated with Ova + PorB and anti-Ova lgG 
levels comparable to those vaccinated with Ova alone. A TLR2-independent 
mechanism of adjuvanticity for PorB could be important given the variability in 
TLR polymorphisms in humans and the role they can play in vaccine response 
[155, 156]. Even a sub-optimal response could afford some measure of 
protection in an individual who might otherwise be unprotected if they carried a 
TLR2 variant that was unresponsive to PorB. 
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The role of the inflammasome and IL-1P in vaccine adjuvant activity is a 
controversial topic, especially in regards to the mechanism of action of alum [85, 
141]. In particular, while TLRs are known to increase transcription and translation 
of pro-IL-1 p, activation of an NLR or AIM2 is still required to cleave pro-caspase-
1 and begin the inflammasome cascade leading to the production of active IL-1 p 
and IL-18 [1 0]. As N. meningitidis PorB is a pore-forming protein, and potassium 
efflux driven by exogenous ATP is sufficient to activate NLRP3 [157], we were 
interested to see if PorB alone would be sufficient to provide both signals to the 
inflammasome. This would provide a novel mechanism for a TLR-based adjuvant 
to stimulate the immune system and could possibly explain some of the TLR2-
independent, MyD88-dependent effects we observed in other experiments. 
However, findings demonstrated that while PorB was indeed capable of 
promoting IL-1P release when given in combination with exogenous ATP, PorB 
alone, like Pam3CS~ and LPS, failed to elicit a strong IL-1 P response. The lack 
of I L-1 p generated by treatment with PorB alone suggests an alternative 
explanation is needed for the weak adjuvant activity of PorB in TLR2 KO mice. 
The absence of inflammasome activation by PorB alone does not rule out the 
inflammasome playing a role in the adjuvant activity of PorB, but does imply that 
some other factor would be required to generate the second signal in vivo. 
Inclusion of such a factor into a vaccine formulation containing PorB could be an 
interesting avenue pursue. 
Chapter 2: Antigen uptake and APC migration 
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In studying antigen uptake and trafficking, I expanded the scope of the 
innate immune network known to be affected by PorB. The role of TLRs and their 
ligands in increasing antigen uptake and processing has been well studied in the 
innate immune response to LPS and other PAMPs [75, 76]. The state of the field 
can now be extended to include PorB in the list of adjuvants known to affect 
antigen uptake. Our lab has previously demonstrated the importance of cytokine 
responses and TLR2 presence in the constellation of effects driven by PorB [25]. 
We have also shown that PorB upregulates activation markers and costimulatory 
molecules on APCs [90]. This research expands the scope of innate immune 
pathways known to be affected by PorB to include the antigen uptake and 
migration fields. The findings presented here support the hypothesis that 
increased antigen uptake in macrophages and dendritic cells is observed in 
response to stimulation with PorB. These results suggest that increased antigen 
uptake and APC migration could play a role in the adjuvant activity of PorB. 
I first examined the ability of PorB to increase antigen uptake in 
macrophages and dendritic cells. It should be noted that a different measure of 
outcomes was required for macrophages and dendritic cells. In the BMDM 
experimental model essentially all of the macrophages took up at least some of 
the labeled Ova, even in the absence of a TLR ligand. This required the use of 
the geometric mean intensity as a marker; results were interpreted as an 
increase in the amount of Ova taken up by each cell . The conclusion, therefore, 
is that PorB increased the amount of antigen taken up by each cell at the earlier 
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time points. To explain the increased antigen uptake, it may be noted that PorB 
forms nanoscale proteosome aggregates in solution [24]. Physical size of 
particles has been implicated in modifying antigen uptake by APCs [147, 158, 
159]. It is possible, therefore, that the physical size of the PorB proteosome 
accelerated the process of phagocytosis once the particle had attached to the 
surface of the cell via TLR2, with the labeled Ova antigen brought along through 
non-covalent adsorption to the proteosome. In this scenario the results observed 
in the presence of PorB would be similar to those of studies on intact pathogens, 
only using a much smaller delivery vehicle. In contrast, in dendritic cells the 
proportion of cells that took up the antigen increased in the presence of PorB. 
These results are consistent with the observation that the inclusion of PorB as an 
adjuvant increases the fraction of dendritic cells positive for antigen in draining 
lymph nodes. Together these results suggest that PorB may act in some way to 
convert dendritic cells from a quiescent state to one in which they actively take 
up antigen more rapidly than stimulation with a soluble TLR ligand. 
In both cell types by 24 hours LPS (and Pam3CSK.t in macrophages) was 
equivalent to PorB in antigen uptake while still remaining higher than control cells 
given Ova alone. This suggests that either PorB acts to increase antigen uptake 
in an alternate manner to LPS or Pam3CSK4, or that it acts through the same 
pathways but in a more rapid manner. To differentiate between these 
hypotheses, we can look to the known effects of TLR ligands on antigen uptake 
and fit them where possible to the observed effects of stimulation with PorB. At 
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earlier time points the nature of antigen uptake in response to stimulation by 
PorB appears quantitatively different from that observed in response to 
stimulation with LPS. It was observed from the fluorescent microscopy studies 
that at 6 hours the distribution of Ova within macrophages appeared to differ 
between cells stimulated with LPS and PorB. This would not fit with a hypothesis 
that stimulation with PorB simply accelerates the same response seen in cells 
stimulated with LPS. Instead, at early time points, a TLR2 dependent, My088 
independent process specific for PorB appears to drive increased antigen uptake 
in response to PorB. As mentioned above, the particulate nature of PorB 
proteosomes may be responsible for this observed effect. As a great deal of 
research has gone into the development of vaccine vehicles that incorporate 
PAMPs attached to nanoparticle structures [160-162], the demonstration that 
PorB may be utilizing particulate mechanisms to increase antigen uptake is 
significant because it represents a combination particulate vector and TLR ligand 
in a single molecule. At later time points, however, PorB, LPS and Pam3CS~ 
may act through the same pathways to increase antigen uptake. Soluble 
ovalbumin is known to be internalized through mannose-receptor mediated 
endocytosis, and the mannose receptor is known to interact with TLR receptor 
dependent processes [163-165]. By the 24 hour time point, this effect could be 
responsible for the increased Ova taken up by cells stimulated with LPS and 
Pam3CS~. As a TLR ligand, it is conceivable that PorB too increases mannose-
receptor mediated endocytosis by the 24 hour time point. The above 
138 
observations of antigen uptake across all time points could therefore be 
explained if at early time points PorB acts to increase antigen uptake through 
TLR2 dependent particulate endocytosis while at later time points the synergistic 
activity of TLR signaling and man nose-receptor mediated endocytosis 
predominates for all TLR ligands. In this model PorB is uniquely suited to 
increase antigen uptake under multiple conditions as compared to alternate 
adjuvants. 
Flow cytometry and microscopy studies jointly suggest a role for PorB in 
increasing migration of antigen-bearing APCs to draining lymph nodes from sites 
of vaccination. Given that PorB increases the percentage of antigen positive 
dendritic cells in the flow cytometry data while the prevalence of DCs out of all 
cells remains the same and the increase in the total size of the lymph node, it 
can be concluded that PorB must act to increase DC migration from the 
periphery. This is in contrast to the competing hypothesis that PorB acts solely to 
increase antigen uptake by resident DCs of the lymph node. As presentation of 
antigen by APCs to T cells in secondary lymphoid tissue is critical in robust 
adaptive immune responses, it is possible that increased migration of APCs may 
play a role in the effectiveness of PorB as a vaccine adjuvant. Further 
characterization of antigen-positive DCs in draining lymph nodes will allow us to 
better differentiate the relative effects of PorB immune stimulating activity on 
draining and resident DCs. Further study of frozen tissue sections may also aid in 
characterization of the antigen-positive cells within the lymph nodes and their 
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relation to other cell types. It would be of interest to determine if the inclusion of 
PorB into the vaccine formulation increased interactions between APCs and 
antigen-specific T ceUs. 
Chapter 3: Transcriptome analysis and systems vaccinology 
In my final aim, I analyzed gene expression in mice vaccinated with PorB 
and a test antigen (OVA) to better characterize the nature of the overall 
responses induced by PorB when used as a vaccine adjuvant. While a great deal 
has been revealed using vaccinomics to understand the responses to single 
injections of vaccines [1 03], much less is understood about the dynamics of 
multi-injections vaccination schedules. This aim therefore addressed two goals: 
opening a new region of the field by examining the course of a multi-injection 
vaccination schedule, and expanding the scope of known adjuvant regulatory 
profiles to include PorB. 
Analysis of microarray data obtained only after three vaccination injections 
revealed minimal differences between mice vaccinated with Ova versus Ova + 
PorB. However, it is known that mice given the PorB adjuvanted vaccine produce 
significantly more antigen-specific antibodies by two weeks after a third 
vaccination, as seen in Aim 1. To explain this discrepancy it was hypothesized 
that key regulatory events driven by the adjuvant must have occurred earlier in 
the vaccination schedule. Our second round of microarray experiments thus 
focused on understanding the kinetics of the entire vaccination schedule to 
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determine both the effects of PorB as an adjuvant and when those effects were 
most apparent. 
To examine the changes in kinetics observed when PorB is used as a 
vaccine adjuvant we constructed multiple kinetic models, and fit the expression 
profiles of mice given each vaccine to each model. The monotonic model 
described genes that either increased or decreased continuously over the course 
of the vaccination schedule. The revertant model, in contrast described genes 
that first increased in expression, then returned to their baseline levels. Gene 
regulation in mice vaccinated with Ova alone correlated well to the monotonic 
model ascribed to classic multi-injection dogma, but it is evident that such a 
model does not accurately describe the response to the adjuvanted vaccine 
formulation. Instead, it is found that a revertant model best describes the 
progress of the response to a PorB adjuvanted vaccine. More detailed analysis 
comparing the reactions individual mice within each group also suggests that the 
inclusion of PorB leads to a more heterogeneous response. That is, while gene 
upregulation trends earlier when an adjuvant is included, gene expression in 
some of the mice may peak after the first injection while other mice maintain 
elevated expression of relevant genes through the third injection. This revertant 
pattern of gene regulation represents a novel finding in the field of systems 
vaccinology, although it is not clear whether it applies only to regulation when 
PorB is used as an adjuvant, or if it could be representative of adjuvanted 
vaccines in general. 
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In addition to changes in the timing of gene regulation, recruitment of a 
significantly larger number of genes relating to innate immunity, TLR signaling, 
and inflammation with the inclusion of PorB as an adjuvant are also seen. As 
PorB is known to be a TLR2 agonist, this is not unexpected. However, this work 
does provide confirmatory evidence that these regulatory events do occur in the 
spleen, a secondary lymphoid organ, and are not restricted to localized activation 
of innate immune cells at the site of injection, where they have previously been 
studied [96]. Additional observations ofT cell recruitment and activation also fall 
into line with previous research on the use of PorB as a vaccine adjuvant that 
demonstrate its ability to convert T independent adaptive immune responses to T 
dependent ones [30]. This pattern of innate immune and inflammatory gene 
induction by PorB is consistent with studies on other vaccines adjuvants [166, 
167]. 
The question of whether the accelerated kinetics of gene expression 
profiles seen with PorB as an adjuvant can be generalized to include all 
adjuvants, or even all TLR ligand adjuvants, remains open. It was observed in 
our analysis of the GSEA results that the use of PorB as an adjuvant leads to the 
upregulation of genes comprising sets defined from those related to multiple 
other PRRs, including TLR3, TLR9 and RIG-I. Upregulated gene enrichment in 
these sets could imply that the responses observed after vaccination with PorB 
may also be seen in when the ligands for these other receptors are used as 
adjuvants. If so, this could imply that the kinetics observed in response to 
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vaccination with PorB as an adjuvant are generally applicable to vaccine 
adjuvants as a whole. The significant changes in responses observed after each 
injection imply that studying a single injection of a vaccine normally given in a 
multi-injection schedule does not accurately capture the entirety of the immune 
response as it develops over the course of the schedule. A single injection may 
be sufficient for many of the highly immunogenic vaccines that have been studied 
to date, and in these cases no longitudinal study would be required. However, 
both vaccines currently in use and in development are designed with the intent of 
requiring multiple injections in order to develop sufficient coverage and protection 
in the general population. Based on the current results, it would be expected that 
many of these vaccines, especially those employing adjuvants to complement 
less-immunogenic antigens, will not progress through gene regulation in a 
monotonic manner. Even if this has not been definitively established as a general 
characteristic of adjuvanted vaccines, the results presented here suggest that the 
potential for non-monotonic regulation needs to be taken into account. 
Conclusions 
The underlying theme of my work has been the characterization of the 
immune stimulating and adjuvant effects of PorB. I investigated multiple 
pathways through with PorB might stimulate the immune system for evidence of 
activity. I confirmed that treatment with PorB does increase surface protein 
expression on macrophages, while ruling out that PorB is sufficient to induce the 
release of IL-1 ~without additional stimulation. I demonstrated that stimulation 
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with PorB does increase antigen uptake by macrophages and dendritic cells, and 
also increases migration of antigen positive dendritic cells to draining lymph 
nodes. In areas where PorB was shown to have activity, I investigated whether 
this activity was TLR2 or MyD88 dependent. While in most cases both genes 
were required for the observed effect, a few surprising counter-examples were 
revealed as well. In particular, stimulation with PorB increased expression of 
CD54 and CD69 in the absence of TLR2, and increased antigen uptake in the 
absence of My088. These results, taken together with the observation that PorB 
still has a minimal adjuvant effect in mice lacking TLR2, suggest that immune 
signaling in response PorB is more complex than previously suspected. 
While studies of the effects of PorB on cells in culture are essential for 
understanding the mechanics behind the activity of PorB, the eventual goal of 
this research is for its use as a vaccine adjuvant. To this end, it is essential to 
study the effects of PorB within a complete immune system, which requires 
animal models. In the research I have presented here, I directly tested whether 
PorB requires TLR2 or My088 to function as a vaccine adjuvant, and found that 
TLR2 is essential for maximal adjuvanticity of PorB, and that MyD88 is required 
for PorB to have any adjuvant effect at all. This agrees well with our lab's 
previous research into the requirements of PorB in stimulating individual 
pathways of innate immunity, and could support a hypothesis that they play a 
role in the adjuvant activity of PorB. In order to expand the scope of known 
immune stimulating activities of PorB, and to better understand the kinetics of the 
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immune response when PorB is used as an adjuvant, I examined the entire 
transcriptome of splenocytes during vaccination with PorB as an adjuvant using 
microarray techniques. This investigation revealed that, when PorB is used as an 
adjuvant, regulation in immune and inflammatory networks was observed that 
was not present in mice vaccinated with antigen alone. These in vivo results 
corroborate earlier findings in our lab into the innate immune stimulating effects 
of PorB in vitro. Additionally, when PorB was included as an adjuvant, gene 
regulatory events were accelerated, with expression in many gene sets peaking 
after the second of three vaccinations, while for mice that did not receive the 
adjuvanted vaccine expression in most genes was still increasing by the third 
vaccination. These results report new activity for PorB, and could suggest that 
some of its adjuvant effect is due to accelerated immune regulation . 
My work expands our knowledge of the effects of PorB as an agonist of 
the innate immune system and as a vaccine adjuvant. I have characterized 
known immune responses in new cell types, and new responses not previously 
studied for PorB, both in wild type and knockout cells. These studies are 
important in that they both better characterize the responses induced by PorB, 
and suggest new hypotheses for mechanisms that could explain its adjuvant 
activity. In studying the adjuvant activity of PorB, I have demonstrated the 
necessity of TLR2 and MyD88 for PorB to have its full adjuvant effect, and in 
doing so, begun the process of determining which of the known immune 
stimulating effects of PorB are required for its adjuvanticity. This list of known 
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effects, in turn, has been expanded through the microarray analysis of gene 
regulation induced when PorB is used as a vaccine adjuvant. In observing 
accelerated gene regulation when PorB is used as a vaccine adjuvant, I have 
described an effect that is not only new for PorB, but has never been described 
in this manner for any vaccine adjuvant. 
Future Directions 
The broad direction of our lab's research is to understand the functions of 
vaccine adjuvants in general, and PorB in particular. While the data presented 
here does extend our knowledge of the effects of PorB, it also opens up new 
avenues of research. As described above, evidence has been obtained that PorB 
possesses a TLR2-independent mechanism of adjuvanticity, based on the finding 
of increased antigen-specific antibodies when PorB is included in a vaccine given 
to TLR2 KO mice. While it is known that this adjuvanticity is ablated in My088 
KO mice, the specific mechanisms at play are not yet known, although calcium 
signaling due to pore-forming activity by PorB has been suggested. A TLR2 
dependent, but My088 independent, mechanism for PorB driven increased 
antigen uptake has also been observed. Further investigation into the interaction 
of PorB with antigen uptake may focus on demonstrating increased antigen 
processing and presentation on the surface of APCs in the presence of PorB, 
potentially related to the particulate nature of PorB proteosomes. Further 
investigation into the observation of potential changes to the intracellular 
distribution of Ova-A594 in the presence of PorB could be carried out through 
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labeling of endosomal compartments or analysis of peptide cleavage and 
presentation on Class I or Class II MHC. Given the increase in antigen-bearing 
APCs recruited to drainin9 lymph nodes when PorB is included as a vaccine 
adjuvant, it would be interesting to determine if these APCs also associate more 
closely with antigen-specific T cells. Experiments using labeled T cells and either 
fresh frozen sections or two-photon microscopy [78, 81] have been used in the 
field to investigate similar questions. 
The transcriptome analysis of the inclusion of PorB as a vaccine adjuvant 
could expand in multiple directions. Having established a profile for PorB as an 
adjuvant over the course of three injections, it would be interesting to expand the 
scope of the project to include additional adjuvants of relevance to modern 
vaccinology. Repeating existing experiments with additional adjuvants would 
enable highlighting the differences between each, and determining if the 
accelerated kinetics we observed in response to PorB are consistent across 
some or all adjuvants. A more comprehensive comparison between adjuvants 
could also allow for the rational design of future vaccines and the selection of 
specific adjuvants tailored to meet specific vaccine requirements for immune 
stimulation , innate and adaptive responses, or other criteria. Taking a more 
focused approach to the data thus far collected , the studies on PorB presented 
so far have uncovered regulation of a number of targets of interest. In particular 
multiple miRNAs have been observed that exhibited either revertant regulation 
when PorB was included as an adjuvant or were consistently expressed at higher 
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levels when PorB was included in the vaccine formulation . Experimentation to 
confirm the regulation of these miRNAs, and to determine their role, if any, in the 
immune response to PorB, would be a highly novel finding in the field of adjuvant 
immunology. 
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